Intellipharmaceutics International (IPCIF) 6-K 21 Jul 22 2022 Q2 Current report (foreign) Financial data

Cover

Cover	6 Months Ended
	May 31, 2022
Cover [Abstract]
Entity Registrant Name	Intellipharmaceutics International Inc.
Entity Central Index Key	0001474835
Document Type	6-K
Amendment Flag	false
Current Fiscal Year End Date	--11-30
Document Period End Date	May 31, 2022
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2022
Entity File Number	000-53805

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	May 31, 2022	Nov. 30, 2021
Current
Cash	$ 372,795	$ 771,945
Investment tax credits	268,179	268,179
Prepaid expenses, sundry and other assets	267,313	62,192
Current Assets	908,287	1,102,316
Property and equipment, net (Note 4)	891,153	994,109
Right-of-use asset (Note 6)	82,143	0
Total Assets	1,881,583	2,096,425
Liabilities Current
Accounts payable	4,285,339	3,779,550
Accrued liabilities	2,712,045	2,272,610
Employee costs payable	2,671,154	2,263,944
Operating lease liability (Note 6)	83,185	0
Income tax payable	18,178	18,178
Promissory notes payable (Note 5)	167,693	165,878
Convertible debentures (Note 5)	1,800,000	1,751,483
Total Liabilities	11,737,594	10,251,643
Shareholders' deficiency
Issued and outstanding 33,092,665 common shares	49,175,630	49,175,630
Additional paid-in capital	44,647,269	44,626,436
Accumulated other comprehensive income	284,421	284,421
Accumulated deficit	(103,963,331)	(102,241,705)
Shareholders' deficiency (Equity)	(9,856,011)	(8,155,218)
Contingencies (Note 12)
Liabilities and Shareholders' deficiency (Equity)	$ 1,881,583	$ 2,096,425

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - shares	May 31, 2022	Nov. 30, 2021	Nov. 30, 2020
Consolidated Balance Sheets
Common shares, issued	33,092,665	33,092,665	23,678,105
Common shares, outstanding	33,092,665	33,092,665	23,678,105

Condensed Unaudited Interim Con

Condensed Unaudited Interim Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		6 Months Ended
	May 31, 2022	May 31, 2021	May 31, 2022	May 31, 2021
Revenue
Licensing (Note 3)	$ 0	$ 93,427	$ 0	$ 93,427
Other revenue	0	0	16,978	0
Total revenue	0	93,427	16,978	93,427
Cost of good sold
Cost of goods sold	0	0	0	0
Gross Margin	0	93,427	16,978	93,427
Expenses
Research and development	956,851	481,679	1,434,408	1,029,164
Selling, general and administrative	243,501	453,219	504,359	625,265
Depreciation (Note 4)	51,479	65,381	102,957	130,763
Total Expenses	1,251,831	1,000,279	2,041,724	1,785,192
Loss from operations	(1,251,831)	(906,852)	(2,024,746)	(1,691,765)
Net foreign exchange gain	(15,357)	(13,896)	(22,851)	(77,949)
Interest expense	(73,466)	(79,436)	(174,029)	(155,036)
Gain on disposal of assets	500,000	0	500,000	0
Net loss and comprehensive loss	$ (840,654)	$ (1,000,184)	$ (1,721,626)	$ (1,924,750)
Loss per common share, basic and diluted	$ (0.03)	$ (0.04)	$ (0.05)	$ (0.07)
Weighted average number of common shares outstanding, basic and diluted	33,092,665	27,771,392	33,092,665	25,747,239

Condensed Unaudited Interim C_2

Condensed Unaudited Interim Consolidated Statements of Shareholders' Equity (Deficiency) - USD ($)	Total	Capital stock	Additional paid-in capital	Accumulated other comprehensive income	Accumulated deficit
Balance, shares at Nov. 30, 2020		23,678,105
Balance, amount at Nov. 30, 2020	$ (6,313,589)	$ 46,144,402	$ 44,354,138	$ 284,421	$ (97,096,550)
Stock options to employees (Note 8)	11,985	$ 0	11,985	0	0
Proceeds from private placement financing (Note 7), shares		9,414,560
Proceeds from private placement financing (Note 7), amount	3,069,448	$ 3,069,448	0	0	0
Cost of private placement financing (Note 7)	(38,220)	(38,220)	0	0	0
Beneficial conversion feature related to Debentures (Note 5)	166,667	0	166,667	0	0
Net loss	(1,924,750)	$ 0	0	0	(1,924,750)
Balance, shares at May. 31, 2021		33,092,665
Balance, amount at May. 31, 2021	(5,028,459)	$ 49,175,630	44,532,790	284,421	(99,021,300)
Balance, shares at Nov. 30, 2021		33,092,665
Balance, amount at Nov. 30, 2021	(8,155,218)	$ 49,175,630	44,626,436	284,421	(102,241,705)
Beneficial conversion feature related to Debentures (Note 5)	20,833	0	20,833	0	0
Net loss	(1,721,626)	$ 0	0	0	(1,721,626)
Balance, shares at May. 31, 2022		33,092,665
Balance, amount at May. 31, 2022	$ (9,856,011)	$ 49,175,630	$ 44,647,269	$ 284,421	$ (103,963,331)

Condensed Unaudited Interim C_3

Condensed Unaudited Interim Consolidated Statements of Cash Flows - USD ($)	3 Months Ended		6 Months Ended
	May 31, 2022	May 31, 2021	May 31, 2022	May 31, 2021
Condensed Unaudited Interim Consolidated Statements of Cash Flows
Net loss	$ (840,654)	$ (1,000,184)	$ (1,721,626)	$ (1,924,750)
Items not affecting cash
Depreciation	51,479	65,381	102,957	130,763
Stock-based compensation	0	1,435	0	11,985
Accreted interest	20,834	26,278	69,351	49,882
Non-cash lease expense	40,582	25,705	(82,143)	62,653
Gain on disposal of assets	(500,000)	0	(500,000)	0
Unrealized foreign exchange loss	629	11,922	1,812	13,683
Change in non-cash operating assets & liabilities
Accounts receivable	37,353	(119,255)	0	447,129
Prepaid expenses, sundry and other assets	40,006	(3,696)	(205,121)	33,938
Accounts payable, accrued liabilities and employee costs payable	851,294	262,254	1,352,435	483,521
Operating lease liability	(40,092)	(33,606)	83,185	(71,947)
Cash flows used in operating activities	(338,569)	(763,766)	(899,150)	(763,143)
Financing activities
Proceeds from private placement financing	0	3,069,448	0	3,069,448
Cost related to private placement	0	(38,220)	0	(38,220)
Cash flows provided from financing activities	0	3,031,228	0	3,031,228
Investing activities
Sale of property and equipment	500,000	0	500,000	0
Cash flows provided from investing activities	500,000	0	500,000	0
(Decrease) increase in cash	161,431	2,267,462	(399,150)	2,268,085
Cash, beginning of period	211,364	202,669	771,945	202,046
Cash, end of period	$ 372,795	$ 2,470,131	$ 372,795	$ 2,470,131

Nature of Operations

Nature of Operations	6 Months Ended
	May 31, 2022
Nature of Operations
Nature of Operations	1 Nature of operations Intellipharmaceutics International Inc. (the “Company”) is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. On October 22, 2009, IntelliPharmaCeutics Ltd. (“IPC Ltd. “) and Vasogen Inc. completed a court approved plan of arrangement and merger (the “IPC Arrangement Agreement”), resulting in the formation of the Company, which is incorporated under the laws of Canada. The Company’s common shares are traded on the Toronto Stock Exchange (“TSX”) and the OTCQB Venture Market. The Company earns revenue from non-refundable upfront fees, milestone payments upon achievement of specified research or development, exclusivity milestone payments and licensing and cost-plus payments on sales of resulting products. In November 2013, the U.S. Food and Drug Administration (“FDA”) granted the Company final approval to market the Company’s first product, the 15 mg and 30 mg strengths of the Company’s generic Focalin XR® (dexmethylphenidate hydrochloride extended-release) capsules. In 2017, the FDA granted final approval for the remaining 6 (six) strengths, all of which have been launched. In May 2017, the FDA granted the Company final approval for its second commercialized product, the 50, 150, 200, 300 and 400 mg strengths of generic Seroquel XR® (quetiapine fumarate extended release) tablets, and the Company commenced shipment of all strengths that same month. In November 2018, the FDA granted the Company final approval for its venlafaxine hydrochloride extended-release capsules in the 37.5, 75, and 150 mg strengths. Going concern The condensed unaudited interim consolidated financial statements are prepared on a going concern basis, which assumes that the Company will be able to meet its obligations and continue its operations for the next twelve months. The Company has incurred losses from operations since inception and has reported losses of $840,654 and $1,721,626 for the three and six months ended May 31, 2022 (three and six months ended May 31, 2021 - $1,000,184 and $1,924,750) and has an accumulated deficit of $103,963,331 as at May 31, 2022 (November 30, 2021 - $102,241,705). The Company has a working capital deficiency of $10,829,307 as at May 31, 2022 (November 30, 2021 – $9,149,327). The Company has funded its research and development (“R&D”) activities principally through the issuance of securities, loans from related parties, funds from the IPC Arrangement Agreement, and funds received under development agreements. There is no certainty that such funding will be available going forward. These conditions raise substantial doubt about its ability to continue as a going concern and realize its assets and pay its liabilities as they become due. In order for the Company to continue as a going concern and fund any significant expansion of its operation or R&D activities, the Company will require significant additional capital. Although there can be no assurances, such funding may come from revenues from the sales of the Company’s generic Focalin XR® (dexmethylphenidate hydrochloride extended-release) capsules, from revenues from the sales of the Company’s generic Seroquel XR® (quetiapine fumarate extended-release) tablets and from potential partnering opportunities. Other potential sources of capital may include payments from licensing agreements, cost savings associated with managing operating expense levels, other equity and/or debt financings, and/or new strategic partnership agreements which fund some or all costs of product development. The Company’s ultimate success will depend on whether its product candidates receive the approval of the FDA, Health Canada, and the regulatory authorities of the other countries in which its products are proposed to be sold and whether it is able to successfully market approved products. The Company cannot be certain that it will receive FDA, Health Canada, or such other regulatory approval for any of its current or future product candidates, or that it will reach the level of sales and revenues necessary to achieve and sustain profitability, or that the Company can secure other capital sources on terms or in amounts sufficient to meet its needs, or at all. The availability of equity or debt financing will be affected by, among other things, the results of the Company’s R&D, its ability to obtain regulatory approvals, its success in commercializing approved products with its commercial partners and the market acceptance of its products, the state of the capital markets generally, the delisting from Nasdaq (as defined below), strategic alliance agreements, and other relevant commercial considerations. In addition, if the Company raises additional funds by issuing equity securities, its then existing security holders will likely experience dilution, and the incurring of indebtedness would result in increased debt service obligations and could require the Company to agree to operating and financial covenants that would restrict its operations. In the event that the Company does not obtain sufficient additional capital, it will raise substantial doubt about the Company’s ability to continue as a going concern, realize its assets and pay its liabilities as they become due. The Company’s cash outflows are expected to consist primarily of internal and external R&D, legal and consulting expenditures to advance its product pipeline and selling, general and administrative expenses to support its commercialization efforts. Depending upon the results of the Company’s R&D programs, the impact of the litigation against the Company and the availability of financial resources, the Company could decide to accelerate, terminate, or reduce certain projects, or commence new ones. Any failure on its part to successfully commercialize approved products or raise additional funds on terms favorable to the Company or at all, may require the Company to significantly change or curtail its current or planned operations in order to conserve cash until such time, if ever, that sufficient proceeds from operations are generated, and could result in the Company not taking advantage of business opportunities, in the termination or delay of clinical trials or the Company not taking any necessary actions required by the FDA or Health Canada for one or more of the Company’s product candidates, in curtailment of the Company’s product development programs designed to identify new product candidates, in the sale or assignment of rights to its technologies, products or product candidates, and/or its inability to file Abbreviated New Drug Applications (“ANDAs”), Abbreviated New Drug Submissions (“ANDSs”) or New Drug Applications (“NDAs”) at all or in time to competitively market its products or product candidates. The condensed unaudited interim consolidated financial statements do not include any adjustments that might result from the outcome of uncertainties described above. If the going concern assumption no longer becomes appropriate for these condensed unaudited interim consolidated financial statements, then adjustments would be necessary to the carrying values of assets and liabilities, the reported expenses and the balance sheet classifications used. Such adjustments could be material.

Basis of Presentation

Basis of Presentation	6 Months Ended
	May 31, 2022
Basis of Presentation
Basis of Presentation	2.Basis of presentation (a) Basis of consolidation These condensed unaudited interim consolidated financial statements include the accounts of the Company and its wholly owned operating subsidiaries, IPC Ltd., Intellipharmaceutics Corp., and Vasogen Corp. References in these condensed unaudited interim consolidated financial statements to share amounts, per share data, share prices, exercise prices and conversion rates have been adjusted to reflect the effect of the 1-for-10 reverse stock split (known as a share consolidation under Canadian law) (the “reverse split”) which became effective on each of The Nasdaq Stock Market LLC (“Nasdaq”) and TSX at the opening of the market on September 14, 2018. The term “share consolidation” is intended to refer to such reverse split and the terms “pre-consolidation” and “post-consolidation” are intended to refer to “pre-reverse split” and “post-reverse split”, respectively. The Company’s common shares began trading on each of Nasdaq and TSX on a post-split basis under the Company’s existing trade symbol “IPCI” at the opening of the market on September 14, 2018. In accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”), the change was applied retroactively. The condensed unaudited interim consolidated financial statements do not conform in all respects to the annual requirements of U.S. GAAP. Accordingly, these condensed unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended November 30, 2021. These condensed unaudited interim consolidated financial statements have been prepared using the same accounting policies and methods as those used by the Company in the annual audited consolidated financial statements for the year ended November 30, 2021. The condensed unaudited interim consolidated financial statements reflect all adjustments necessary for the fair presentation of the Company’s financial position and results of operation for the interim periods presented. All such adjustments are normal and recurring in nature. All inter-company accounts and transactions have been eliminated on consolidation. (b) Use of estimates The preparation of the condensed unaudited interim consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the period. Actual results could differ from those estimates. Areas where significant judgment is involved in making estimates are the determination of the functional currency; the fair values of financial assets and liabilities; the determination of units of accounting for revenue recognition; the accrual of licensing and milestone revenue; and forecasting future cash flows for assessing the going concern assumption. The ongoing COVID-19 outbreak and pandemic present complex challenges and uncertainties to organizations across the world. Businesses face unprecedented times and with the situation being dynamic, the ultimate duration and magnitude of COVID-19’s impact on the economy and the Company’s business are not known at this time. Travel bans, self-quarantines and social distancing have caused material disruptions to businesses globally, resulting in economic slowdown, with global equity markets experiencing volatility and weakness. The Company has adjusted its R&D and business development/marketing activities according to the pandemic effects as it continues to work to try to ensure that operations continue while remaining committed to keeping its employees safe. The Company has also made arrangements for its employees to work under a government workshare program for eligible current employees whereby the Company is paying personnel only for a certain number of days a week and the Government of Canada provides income support in the form of employment insurance. From late 2019, the Company has had to reduce development activities and staffing levels significantly due to ongoing financial problems which have continued, coupled with the effect of the COVID-19 pandemic. It is not possible to reliably estimate the length and severity of the developments and impact on the future financial results and condition of the Company. The challenges and uncertainties could impair the Company’s ability to raise capital, postpone research activities, impact the Company’s ability to maintain operations and launch new products; it could also impair the value of the Company’s shares and long-lived assets, and materially adversely impact its ability to generate potential future revenue.

Significant Accounting Policies

Significant Accounting Policies	6 Months Ended
	May 31, 2022
Significant Accounting Policies
Significant Accounting Policies	3. Significant accounting policies (a) Revenue recognition The Company accounts for revenue in accordance with the provisions of ASC Topic 606 Revenue from Contracts with Customers (“ASC Topic 606”). Under ASC Topic 606, the Company recognizes revenue when the customer obtains control of promised goods or services, in an amount that reflects the consideration the Company expects to receive in exchange for those goods or services. The Company recognizes revenue following the five-step model prescribed under ASC Topic 606: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) the Company satisfies the performance obligation(s). The Company earns revenue from non-refundable upfront fees, milestone payments upon achievement of specified research or development, exclusivity milestone payments and licensing payments on sales of resulting products. The relevant revenue recognition accounting policy is applied to each separate unit of accounting. Licensing The Company recognizes revenue from the licensing of the Company’s drug delivery technologies, products and product candidates. Under the terms of the licensing arrangements, the Company provides the customer with a right to access the Company’s intellectual property with regards to the license which is granted. Revenue arising from the license of intellectual property rights is recognized over the period the Company transfers control of the intellectual property. The Company has a license and commercialization agreement with Par Pharmaceutical Inc. (“Par”). Under the exclusive territorial license rights granted to Par, the agreement requires that Par manufacture, promote, market, sell and distribute the product. Licensing revenue amounts receivable by the Company under this agreement are calculated and reported to the Company by Par, with amounts generally based upon net product sales and net profit which include estimates for chargebacks, rebates, product returns, and other adjustments. Licensing revenue payments received by the Company from Par under this agreement are not subject to further deductions for chargebacks, rebates, product returns, and other pricing adjustments. Based on this arrangement and the guidance per ASC Topic 606, the Company records licensing revenue over the period the Company transfers control of the intellectual property in the condensed unaudited interim consolidated statements of operations and comprehensive loss. The Company also had a license and commercial supply agreement with Mallinckrodt LLC (“Mallinckrodt”) which provided Mallinckrodt an exclusive license to market, sell and distribute in the U.S. three drug product candidates for which the Company had ANDAs filed with the FDA, one of which (the Company’s generic Seroquel XR®) received final approval from the FDA in 2017. Under the terms of this agreement, the Company was responsible for the manufacture of approved products for subsequent sale by Mallinckrodt in the U.S. market. Following receipt of final FDA approval for its generic Seroquel XR®, the Company began shipment of manufactured product to Mallinckrodt. The Company recorded revenue once Mallinckrodt obtained control of the product and the performance obligation was satisfied. Milestones For milestone payments that are not contingent on sales-based thresholds, the Company applies a most-likely amount approach on a contract-by-contract basis. Management makes an assessment of the amount of revenue expected to be received based on the probability of the milestone outcome. Variable consideration is included in revenue only to the extent that it is probable that the amount will not be subject to a significant reversal when the uncertainty is resolved (generally when the milestone outcome is satisfied). Research and development Under arrangements where the license fees and research and development activities can be accounted for as a separate unit of accounting, non-refundable upfront license fees are deferred and recognized as revenue on a straight-line basis over the expected term of the Company’s continued involvement in the research and development process. Deferred revenue Deferred revenue represents the funds received from clients, for which the revenues have not yet been earned, as the milestones have not been achieved, or in the case of upfront fees for drug development, where the work remains to be completed. (a) Research and development costs Research and development costs related to continued research and development programs are expensed as incurred in accordance with ASC Topic 730 Research and Development. However, materials and equipment are capitalized and amortized over their useful lives if they have alternative future uses. (b) Inventory Inventories comprise of raw materials, work in process, and finished goods, which are valued at the lower of cost or market, on a first-in, first-out basis. Cost for work in process and finished goods inventories includes materials, direct labor, and an allocation of manufacturing overhead. Market for raw materials is replacement cost, and for work in process and finished goods is net realizable value. The Company evaluates the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared with quantities on hand, the price the Company expects to obtain for products in their respective markets compared with historical cost and the remaining shelf life of goods on hand. The recoverability of the cost of any pre-launch inventories with a limited shelf life is evaluated based on the specific facts and circumstances surrounding the timing of the anticipated product launch. (c) Translation of foreign currencies Transactions denominated in currencies other than the Company and its wholly owned operating subsidiaries’ functional currencies, monetary assets and liabilities are translated at the period end rates. Revenue and expenses are translated at rates of exchange prevailing on the transaction dates. All of the exchange gains or losses resulting from these other transactions are recognized in the condensed unaudited interim consolidated statements of operations and comprehensive loss. The functional and reporting currency of the Company and its subsidiaries is the U.S. dollar. (d) Convertible debentures On September 10, 2018, the Company completed a private placement financing (the “2018 Debenture Financing”) of an unsecured convertible debenture in the principal amount of $500,000 (the “2018 Debenture”). At issuance, the conversion price was lower than the market share price, and the value of the beneficial conversion feature related to the 2018 Debenture was allocated to Additional paid-in capital in the condensed unaudited interim consolidated statements of shareholders’ equity (deficiency). On April 4, 2019, a tentative approval from TSX was received for a proposed refinancing of the 2013 Debenture subject to certain conditions being met. As a result of the refinancing, the principal amount owing under the 2013 Debenture was refinanced by a new debenture (the “May 2019 Debenture”). On May 1, 2019, the May 2019 Debenture was issued in the principal amount of $1,050,000, that was originally scheduled to mature on November 1, 2019, bears interest at a rate of 12% per annum and is convertible into 1,779,661 common shares of the Company at a conversion price of $0.59 per common share. At issuance, the conversion option was not characterized as an embedded derivative as it did not meet the criteria of ASC Topic 815, Derivatives and Hedging On November 15, 2019, the Company issued an unsecured convertible debenture in the principal amount of $250,000 (the “November 2019 Debenture”) that was originally scheduled to mature on December 31, 2019, bears interest at a rate of 12% per annum and is convertible into common shares of the Company at a conversion price of $0.12 per share. At issuance, the conversion price was lower than the market share price, and the value of the beneficial conversion feature related to the November 2019 Debenture was allocated to Additional paid-in capital in the condensed unaudited interim consolidated statements of shareholders’ equity (deficiency). (e) Investment tax credits The investment tax credits (“ITC”) receivable are amounts considered recoverable from the Canadian federal and provincial governments under the Scientific Research & Experimental Development (“SR&ED”) incentive program. The amounts claimed under the program represent the amounts based on management estimates of eligible research and development costs incurred during the year. Realization is subject to government approval. Any adjustment to the amounts claimed will be recognized in the year in which the adjustment occurs. Refundable ITCs claimed relating to capital expenditures are credited to property and equipment. Refundable ITCs claimed relating to current expenditures are netted against research and development expenditures. (f) Loss per share Basic loss per share (“EPS”) is computed by dividing the loss attributable to common shareholders by the weighted average number of common shares outstanding. Diluted EPS reflects the potential dilution that could occur from common shares issuable through the exercise or conversion of stock options, restricted stock awards, warrants and convertible securities. In certain circumstances, the conversion of options, warrants and convertible securities are excluded from diluted EPS if the effect of such inclusion would be anti-dilutive. The dilutive effect of stock options is determined using the treasury stock method.

Property and Equipment

Property and Equipment	6 Months Ended
	May 31, 2022
Property and Equipment
Property and Equipment	4. Property and equipment Computer equipment Computer software Furniture and fixtures Laboratory equipment Leasehold improvements Total $ $ $ $ $ Cost Balance at November 30, 2020 631,334 156,059 172,498 5,576,359 1,441,452 7,977,702 Impairment of asset - - - (514,502 ) - (514,502 ) Balance at November 30, 2021 631,334 156,059 172,498 5,061,857 1,441,452 7,463,200 Balance at May 31, 2022 631,334 156,059 172,498 5,061,857 1,441,452 7,463,200 Accumulated depreciation Balance at November 30, 2020 536,697 152,942 145,614 3,930,860 1,441,452 6,207,565 Depreciation 28,391 1,558 5,377 226,200 - 261,526 Balance at November 30, 2021 565,088 154,500 150,991 4,157,060 1,441,452 6,469,091 Depreciation 9,935 390 2,151 90,480 - 102,956 Balance at May 31, 2022 575,023 154,890 153,142 4,247,540 1,441,452 6,572,047 Net book value at: November 30, 2021 66,246 1,559 21,507 904,797 - 994,109 May 31, 2022 56,311 1,169 19,356 814,317 - 891,153 Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Impairment is assessed by comparing the carrying amount of an asset with the sum of the undiscounted cash flows expected from its use and disposal, and as such requires the Company to make significant estimates on expected revenues from the commercialization of its products and services and the related expenses. The Company records a write-down for long-lived assets which have been abandoned and do not have any residual value. Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Impairment is assessed by comparing the carrying amount of an asset with the sum of the undiscounted cash flows expected from its use and disposal, and as such requires the Company to make significant estimates on expected revenues from the commercializationof its products and services and the related expenses. The Company records a write-down for long-lived assets which have been abandoned and do not have any residual value. During the year ended November 30, 2021, the Company recorded a $514,502 write-down of long-lived assets.

Convertible debentures and prom

Convertible debentures and promissory notes payable	6 Months Ended
	May 31, 2022
Convertible debentures and promissory notes payable
Convertible debentures and promissory notes payable	5. Convertible debentures and promissory notes payable (a) Convertible debentures Amounts due to the related parties are payable to two shareholders who are also officers and directors of the Company. February 28, November 30, 2022 2021 Convertible debenture payable to two directors and officers of the Company, unsecured, 10% annual interest rate, payable monthly (“2018 Debenture”) $ 500,000 $ 500,000 Convertible debenture payable to two directors and officers of the Company, unsecured, 12% annual interest rate, payable monthly (“May 2019 Debenture”) 1,050,000 1,050,000 Convertible debenture payable to two directors and officers of the Company, unsecured, 12% annual interest rate, payable monthly (“November 2019 Debenture”) 250,000 201,483 $ 1,800,000 $ 1,751,483 On January 10, 2013, the Company completed a private placement financing of the unsecured convertible 2013 Debenture in the original principal amount of $1.5 million, which was originally scheduled to mature on January 1, 2015. The 2013 Debenture bore interest at a rate of 12% per annum, payable monthly, was pre-payable at any time at the option of the Company and was convertible at any time into common shares at a conversion price of $30.00 per common share at the option of the holder. Dr. Isa Odidi and Dr. Amina Odidi, shareholders, directors and executive officers of the Company purchased the 2013 Debenture and provided the Company with the original $1.5 million of the proceeds for the 2013 Debenture. Effective October 1, 2014, the maturity date for the 2013 Debenture was extended to July 1, 2015. Under ASC Subtopic 470-50, the change in the debt instrument was accounted for as a modification of debt. The increase in the fair value of the conversion option at the date of the modification, in the amount of $126,414, was recorded as a reduction in the carrying value of the debt instrument with a corresponding increase to Additional paid-in capital. The carrying amount of the debt instrument was accreted over the remaining life of the 2013 Debenture using a 15% effective rate of interest. Effective June 29, 2015, the July 1, 2015 maturity date for the 2013 Debenture was further extended to January 1, 2016. Under ASC Subtopic 470-50, the change in the maturity date for the debt instrument resulted in an extinguishment of the original 2013 Debenture as the change in the fair value of the embedded conversion option was greater than 10% of the carrying amount of the 2013 Debenture. In accordance with ASC Section 470-50-40 Debt-Modifications and Extinguishments-Derecognition, the 2013 Debenture was recorded at fair value. The difference between the fair value of the convertible 2013 Debenture after the extension and the net carrying value of the 2013 Debenture prior to the extension of $114,023 was recognized as a loss on the statement of operations and comprehensive loss. The carrying amount of the debt instrument was accreted to the face amount of the 2013 Debenture over the remaining life of the 2013 Debenture using a 14.6% effective rate of interest. Effective December 8, 2015, the January 1, 2016 maturity date for the 2013 Debenture was further extended to July 1, 2016. Under ASC Subtopic 470-50, the change in the debt instrument was accounted for as a modification of debt. The increase in the fair value of the conversion option at the date of the modification, in the amount of $83,101, was recorded as a reduction in the carrying value of the debt instrument with a corresponding increase to Additional paid-in capital. The carrying amount of the debt instrument was accreted over the remaining life of the 2013 Debenture using a 6.6% effective rate of interest. Effective May 26, 2016, the July 1, 2016 maturity date for the 2013 Debenture was further extended to December 1, 2016. Under ASC Subtopic 470-50, the change in the debt instrument was accounted for as a modification of debt. The increase in the fair value of the conversion option at the date of the modification, in the amount of $19,808, was recorded as a reduction in the carrying value of the debt instrument with a corresponding increase to Additional paid-in capital. The carrying amount of the debt instrument was accreted over the remaining life of the 2013 Debenture using a 4.2% effective rate of interest. Effective December 1, 2016, the maturity date for the 2013 Debenture was further extended to April 1, 2017and a principal repayment of $150,000 was made at the time of the extension. Under ASC Subtopic 470-50, the change in the debt instrument was accounted for as a modification of debt. The increase in the fair value of the conversion option at the date of the modification, in the amount of $106,962, was recorded as a reduction in the carrying value of the debt instrument with a corresponding increase to Additional paid-in capital. The carrying amount of the debt instrument was accreted over the remaining life of the 2013 Debenture using a 26.3% effective rate of interest. Effective March 28, 2017, the maturity date for the 2013 Debenture was further extended to October 1, 2017. Under ASC Subtopic 470-50, the change in the debt instrument was accounted for as a modification of debt. The increase in the fair value of the conversion option at the date of the modification, in the amount of $113,607, was recorded as a reduction in the carrying value of the debt instrument with a corresponding increase to Additional paid-in capital. The carrying amount of the debt instrument was accreted over the remaining life of the 2013 Debenture using a 15.2% effective rate of interest. Effective September 28, 2017, the maturity date for the 2013 Debenture was further extended to October 1, 2018. Under ASC Subtopic 470-50, the change in the debt instrument was accounted for as a modification of debt. The increase in the fair value of the conversion option at the date of the modification, in the amount of $53,227, was recorded as a reduction in the carrying value of the debt instrument with a corresponding increase to Additional paid-in capital. The carrying amount of the debt instrument was accreted over the remaining life of the 2013 Debenture using a 4.9% effective rate of interest. Effective October 1, 2018, the maturity date for the 2013 Debenture was further extended to April 1, 2019. Under ASC Subtopic 470-50, the change in the debt instrument was accounted for as an extinguishment of debt. At the date of extinguishment, the Company derecognized the carrying amount of convertible debt of $1,350,000 and recorded the new convertible debt at the fair value of $1,350,000, resulting in no gain or loss. The carrying amount of the debt instrument was accreted over the remaining life of the 2013 Debenture using a nominal effective rate of interest. In December 2018, a principal repayment of $300,000 was made on the 2013 Debenture to Drs. Isa and Amina Odidi. Effective April 1, 2019, the maturity date for the 2013 Debenture was further extended to May 1, 2019.Under ASC Subtopic 470-50, the change in the debt instrument was accounted for as an extinguishment of debt. At the date of extinguishment, the Company derecognized the carrying amount of convertible debt of $1,050,000 and recorded the new convertible debt at the fair value of $1,050,000, resulting in no gain or loss. The carrying amount of the debt instrument was accreted over the remaining life of the 2013 Debenture using a nominal effective rate of interest. On April 4, 2019, a tentative approval from TSX was received for a proposed refinancing of the 2013 Debenture subject to certain conditions being met. As a result of the refinancing, the principal amount owing under the 2013 Debenture was refinanced by the May 2019 Debenture. On May 1, 2019, the May2019 Debenture was issued in the principal amount of $1,050,000, that was originally scheduled to mature on November 1, 2019, bears interest at a rate of 12% per annum and is convertible into 1,779,661 common shares of the Company at a conversion price of $0.59 per common share. Dr. Isa Odidi and Dr. Amina Odidi, who are shareholders, directors, and executive officers of the Company, are the holders of the May 2019 Debenture. Effective November 1, 2019, the maturity date for the May 2019 Debenture was extended to December31, 2019.Under ASC Subtopic 470-50, the change in the debt instrument was accounted for as an extinguishment of debt. At the date of extinguishment, the Company derecognized the carrying amount of convertible debt of $1,050,000 and recorded the new convertible debt at the fair value of $1,050,000, resulting in no gain or loss. The carrying amount of the debt instrument was accreted over the remaining life of the May 2019 Debenture using a nominal effective rate of interest. Effective December 31, 2019, the December 31, 2019 maturity date for the May 2019 Debenture was further extended to February 1, 2020. Under ASC Subtopic 470-50, the change in the debt instrument was accounted for as an extinguishment of debt. At the date of extinguishment, the Company derecognized the carrying amount of convertible debt of $1,050,000 and recorded the new convertible debt at the fair value of $1,050,000, resulting in no gain or loss. As the conversion price was lower than the market share price, the beneficial conversion feature valued at December 31, 2019 of $427,119 was allocated to Additional paid-in capital. Subsequently, the fair value of the May 2019 Debenture was accreted over the remaining life of the May 2019 Debenture using an effective rate of interest of 782.7%. Effective January 31, 2020, the February 1, 2020 maturity date was further extended to March 31, 2020.Under ASC Subtopic 470-50, the change in the debt instrument was accounted for as an extinguishment of debt. At the date of extinguishment, the Company derecognized the carrying amount of convertible debt of $1,050,000 and recorded the new convertible debt at the fair value of $1,050,000, resulting in no gain or loss. The carrying amount of the debt instrument was accreted over the remaining life of the May 2019 Debenture using a nominal effective rate of interest. Effective March31, 2020, the maturity date for the May 2019 Debenture was further extended to May 15, 2020.Under ASC Subtopic 470-50, the change in the debt instrument was accounted for as an extinguishment of debt. At the date of extinguishment, the Company derecognized the carrying amount of convertible debt of $1,050,000 and recorded the new convertible debt at the fair value of $1,050,000, resulting in no gain or loss. The carrying amount of the debt instrument was accreted over the remaining life of the May 2019 Debenture using a nominal effective rate of interest. Effective May 15, 2020, the maturity date for the May 2019 Debenture was further extended to June 12, 2020.Under ASC Subtopic 470-50, the change in the debt instrument was accounted for as an extinguishment of debt. At the date of extinguishment, the Company derecognized the carrying amount of convertible debt of $1,050,000 and recorded the new convertible debt at the fair value of $1,050,000, resulting in no gain or loss. The carrying amount of the debt instrument was accreted over the remaining life of the May 2019 Debenture using a nominal effective rate of interest. Effective June 12, 2020, the maturity date for the May 2019 Debenture was further extended to July 15, 2020.Under ASC Subtopic 470-50, the change in the debt instrument was accounted for as an extinguishment of debt. At the date of extinguishment, the Company derecognized the carrying amount of convertible debt of $1,050,000 and recorded the new convertible debt at the fair value of $1,050,000, resulting in no gain or loss. The carrying amount of the debt instrument was accreted over the remaining life of the May 2019 Debenture using a nominal effective rate of interest. Effective July 15, 2020, the maturity date for the May 2019 Debenture was further extended to December 31, 2020.Under ASC Subtopic 470-50, the change in the debt instrument was accounted for as an extinguishment of debt. At the date of extinguishment, the Company derecognized the carrying amount of convertible debt of $1,050,000 and recorded the new convertible debt at the fair value of $1,050,000, resulting in no gain or loss. The carrying amount of the debt instrument is accreted over the remaining life of the May 2019 Debenture using a nominal effective rate of interest. Effective December 31, 2020, the maturity date for the May 2019 Debenture was further extended to May 31, 2021. Under ASC Subtopic 470-50, the change in the debt instrument was accounted for as an extinguishment of debt. At the date of extinguishment, the Company derecognized the carrying amount of convertible debt of $1,050,000 and recorded the new convertible debt at the fair value of $1,050,000, resulting in no gain or loss. The carrying amount of the debt instrument is accreted over the remaining life of the May 2019 Debenture using a nominal effective rate of interest. Effective May 31, 2021, the maturity date for the May 2019 Debenture was further extended to July 31, 2021. Under ASC Subtopic 470-50, the change in the debt instrument was accounted for as an extinguishment of debt. At the date of extinguishment, the Company derecognized the carrying amount of convertible debt of $1,050,000 and recorded the new convertible debt at the fair value of $1,050,000, resulting in no gain or loss. The carrying amount of the debt instrument is accreted over the remaining life of the May 2019 Debenture using a nominal effective rate of interest. Effective July 31, 2021, the maturity date for the May 2019 Debenture was further extended to October 31, 2021. Under ASC Subtopic 470-50, the change in the debt instrument was accounted for as an extinguishment of debt. At the date of extinguishment, the Company derecognized the carrying amount of convertible debt of $1,050,000 and recorded the new convertible debt at the fair value of $1,050,000, resulting in no gain or loss. The carrying amount of the debt instrument is accreted over the remaining life of the May 2019 Debenture using a nominal effective rate of interest. Effective October 31, 2021, the maturity date for the May 2019 Debenture was further extended to February 28, 2022. Under ASC Subtopic 470-50, the change in the debt instrument was accounted for as an extinguishment of debt. At the date of extinguishment, the Company derecognized the carrying amount of convertible debt of $1,050,000 and recorded the new convertible debt at the fair value of $1,050,000, resulting in no gain or loss. The carrying amount of the debt instrument is accreted over the remaining life of the May 2019 Debenture using a nominal effective rate of interest. Effective February 28, 2022, the maturity date for the May 2019 Debenture was further extended to May 31, 2022. Under ASC Subtopic 470-50, the change in the debt instrument was accounted for as an extinguishment of debt. At the date of extinguishment, the Company derecognized the carrying amount of convertible debt of $1,050,000 and recorded the new convertible debt at the fair value of $1,050,000, resulting in no gain or loss. The carrying amount of the debt instrument is accreted over the remaining life of the May 2019 Debenture using a nominal effective rate of interest. Effective May 31, 2022, the maturity date for the May 2019 Debenture was further extended to November 30, 2022. Under ASC Subtopic 470-50, the change in the debt instrument was accounted for as an extinguishment of debt. At the date of extinguishment, the Company derecognized the carrying amount of convertible debt of $1,050,000 and recorded the new convertible debt at the fair value of $1,050,000, resulting in no gain or loss. The carrying amount of the debt instrument is accreted over the remaining life of the May 2019 Debenture using a nominal effective rate of interest. On September 10, 2018, the Company completed a private placement financing of the unsecured convertible 2018 Debenture in the principal amount of $0.5 million. The 2018 Debenture matured on September 1, 2020. The 2018 Debenture bore interest at a rate of 10% per annum, payable monthly, was pre-payable at any time at the option of the Company and was convertible at any time into common shares of the Company at a conversion price of $3.00 per common share at the option of the holder. Dr. Isa Odidi and Dr. Amina Odidi, who are shareholders, directors and executive officers of the Company provided the Company with the $0.5 million of the proceeds for the 2018 Debenture. At issuance, as the conversion price was lower than the market share price, the beneficial conversion feature valued at September 10, 2018 of $66,667 was allocated to Additional paid-in capital. Subsequently, the fair value of the 2018 Debenture was accreted over the remaining life of the 2018 Debenture using an effective rate of interest of 7.3%. Effective September 1, 2020, the maturity date for the 2018 Debenture was further extended to November 30, 2020.Under ASC 470-50, the change in the debt instrument was accounted for as an extinguishment of debt. At the date of extinguishment, the Company derecognized the carrying amount of convertible debt of $0.5 million and recorded the new convertible debt at the fair value of $0.5 million, resulting in no gain or loss. The carrying amount of the debt instrument is accreted over the remaining life of the 2018 Debenture using a nominal effective rate of interest. Effective November 30, 2020, the maturity date for the 2018 Debenture was further extended to May 31, 2021. Under ASC Subtopic 470-50, the change in the debt instrument was accounted for as an extinguishment of debt. At the date of extinguishment, the Company derecognized the carrying amount of convertible debt of $0.5 million and recorded the new convertible debt at the fair value of $0.5 million, resulting in no gain or loss. The carrying amount of the debt instrument is accreted over the remaining life of the 2018 Debenture using a nominal effective rate of interest. Effective May 31, 2021, the maturity date for the 2018 Debenture was further extended to July 31, 2021. Under ASC Subtopic 470-50, the change in the debt instrument was accounted for as an extinguishment of debt. At the date of extinguishment, the Company derecognized the carrying amount of convertible debt of $0.5 million and recorded the new convertible debt at the fair value of $0.5 million, resulting in no gain or loss. The carrying amount of the debt instrument is accreted over the remaining life of the 2018 Debenture using a nominal effective rate of interest. Effective July 31, 2021, the maturity date for the 2018 Debenture was further extended to October 31, 2021. Under ASC Subtopic 470-50, the change in the debt instrument was accounted for as an extinguishment of debt. At the date of extinguishment, the Company derecognized the carrying amount of convertible debt of $0.5 million and recorded the new convertible debt at the fair value of $0.5 million, resulting in no gain or loss. The carrying amount of the debt instrument is accreted over the remaining life of the 2018 Debenture using a nominal effective rate of interest. Effective October 31, 2021, the maturity date for the 2018 Debenture was further extended to February 28, 2022. Under ASC Subtopic 470-50, the change in the debt instrument was accounted for as an extinguishment of debt. At the date of extinguishment, the Company derecognized the carrying amount of convertible debt of $0.5 million and recorded the new convertible debt at the fair value of $0.5 million, resulting in no gain or loss. The carrying amount of the debt instrument is accreted over the remaining life of the 2018 Debenture using a nominal effective rate of interest. Effective February 28, 2022, the maturity date for the 2018 Debenture was further extended to May 31, 2022. Under ASC Subtopic 470-50, the change in the debt instrument was accounted for as an extinguishment of debt. At the date of extinguishment, the Company derecognized the carrying amount of convertible debt of $0.5 million and recorded the new convertible debt at the fair value of $0.5 million, resulting in no gain or loss. The carrying amount of the debt instrument is accreted over the remaining life of the 2018 Debenture using a nominal effective rate of interest. Effective May 31, 2022, the maturity date for the 2018 Debenture was further extended to November 30, 2022. Under ASC Subtopic 470-50, the change in the debt instrument was accounted for as an extinguishment of debt. At the date of extinguishment, the Company derecognized the carrying amount of convertible debt of $0.5 million and recorded the new convertible debt at the fair value of $0.5 million, resulting in no gain or loss. The carrying amount of the debt instrument is accreted over the remaining life of the 2018 Debenture using a nominal effective rate of interest. On August 26, 2019, the Company completed a private placement financing of the unsecured August 2019 Debenture in the principal amount of $140,800. The August 2019 Debenture was originally scheduled to mature on August 26, 2020, bore interest at a rate of 8% per annum, was pre-payable at any time at the option of the Company up to 180 days from date of issuance with pre-payment penalties ranging from 5% - 30% and was convertible at the option of the holder into common shares after 180 days at a conversion price which was equal to 75% of the market price (defined as the average of the lowest three (3) trading prices for the common shares during the twenty (20) trading day period prior to the conversion date).The Company incurred $15,800 in debt issuance costs of which $7,031 was debited to Additional paid-in capital and $8,769 was offset against the convertible debenture. At issuance, as the conversion price was lower than the market share price, the beneficial conversion feature valued at August 26, 2019 of $62,655 was allocated to Additional paid-in capital. Subsequently, the fair value of the August 2019 Debenture was accreted over the remaining life of the August 2019 Debenture using an effective rate of interest of 77.1%. In November 2019, the August 2019 Debenture was fully paid, and the value of the beneficial conversion feature was recalculated at settlement in the amount of $88,652, which was offset to Additional paid-in capital and $4,419 gain on settlement was recognized in the consolidated statements of operations and comprehensive loss. On November 15, 2019, the Company completed a private placement financing of the unsecured convertible November 2019 Debenture in the principal amount of $0.25 million. The November 2019 Debenture was originally scheduled to mature on December31, 2019. The November 2019 Debenture bore interest at a rate of 12% per annum, payable monthly, was pre-payable at any time at the option of the Company and was convertible at any time into common shares of the Company at a conversion price of $0.12 per common share at the option of the holder. Dr. Isa Odidi and Dr. Amina Odidi, who are shareholders, directors and executive officers of the Company provided the Company with the $0.25 million of the proceeds for the November 2019 Debenture. At issuance, as the conversion price was lower than the market share price, the beneficial conversion feature valued at November 15, 2019 of $41,667 was allocated to Additional paid-in capital. Subsequently, the fair value of the November 2019 Debenture was accreted over the remaining life of the November 2019 Debenture using an effective rate of interest of 152.4%. Effective January 31, 2020, the December 31, 2019 maturity date for the November 2019 Debenture was further extended to March 31, 2020.Under ASC Subtopic 470-50, the change in the debt instrument was accounted for as an extinguishment. In accordance with ASC paragraph 470-50-40-2, extinguishment transactions between related entities are treated as capital transactions. At the date of extinguishment, the Company derecognized the carrying amount of convertible debt of $250,000 and recorded the new convertible debt at the fair value of $250,000, resulting in no gain or loss. As the conversion price was lower than the market share price, the beneficial conversion feature valued at January 31, 2020 of $125,000 was allocated to Additional paid-in capital. Subsequently, the fair value of the November 2019 Debenture was accreted over the remaining life of the November 2019 Debenture using an effective rate of interest of 504.4%. Effective March 31, 2020, the maturity date for the November 2019 Debenture was further extended to May 15, 2020.Under ASC Subtopic 470-50, the change in the debt instrument was accounted for as an extinguishment. In accordance with ASC paragraph 470-50-40-2, extinguishment transactions between related entities are treated as capital transactions. At the date of extinguishment, the Company derecognized the carrying amount of convertible debt of $250,000 and recorded the new convertible debt at the fair value of $250,000, resulting in no gain or loss. As the conversion price was lower than the market share price, the beneficial conversion feature valued at March 31, 2020 of $20,833was allocated to Additional paid-in capital. Subsequently, the fair value of the November 2019Debenture was accreted over the remaining life of the November 2019 Debenture using an effective rate of interest of 72.4%. Effective May 15, 2020, the maturity date for the November 2019 Debenture was further extended to June 12, 2020.Under ASC Subtopic 470-50, the change in the debt instrument was accounted for as an extinguishment. In accordance with ASC paragraph 470-50-40-2, extinguishment transactions between related entities are treated as capital transactions. At the date of extinguishment, the Company derecognized the carrying amount of convertible debt of $250,000 and recorded the new convertible debt at the fair value of $250,000, resulting in no gain or loss. As the conversion price was lower than the market share price, the beneficial conversion feature valued at May 15, 2020 of $41,667was allocated to Additional paid-in capital. Subsequently, the fair value of the November 2019 Debenture was accreted over the remaining life of the November 2019 Debenture using an effective rate of interest of 260.9%. Effective June 12, 2020, the maturity date for the November 2019 Debenture was further extended to July 15, 2020. Under ASC Subtopic 470-50, the change in the debt instrument was accounted for as an extinguishment. In accordance with ASC paragraph 470-50-40-2, extinguishment transactions between related entities are treated as capital transactions. At the date of extinguishment, the Company derecognized the carrying amount of convertible debt of $250,000 and recorded the new convertible debt at the fair value of $250,000, resulting in no gain or loss. As the conversion price was lower than the market share price, the beneficial conversion feature valued at June 12, 2020 of $41,666 was allocated to Additional paid-in capital. Subsequently, the fair value of the November 2019 Debenture was accreted over the remaining life of the November 2019 Debenture using an effective rate of interest of 211.4%. Effective July 15, 2020, the maturity date for the November 2019 Debenture was further extended to December 31, 2020.Under ASC Subtopic 470-50, the change in the debt instrument was accounted for as an extinguishment. In accordance with ASC paragraph 470-50-40-2, extinguishment transactions between related entities are treated as capital transactions. At the date of extinguishment, the Company derecognized the carrying amount of convertible debt of $250,000 and recorded the new convertible debt at the fair value of $250,000, resulting in no gain or loss. As the conversion price was lower than the market share price, the beneficial conversion feature valued at July 15, 2020 of $41,667 Effective December 31, 2020, the maturity date for the November 2019 Debenture was further extended to May 31, 2021. Under ASC Subtopic 470-50, the change in the debt instrument was accounted for as an extinguishment. In accordance with ASC paragraph 470-50-40-2, extinguishment transactions between related entities are treated as capital transactions. At the date of extinguishment, the Company derecognized the carrying amount of convertible debt of $250,000 and recorded the new convertible debt at the fair value of $250,000, resulting in no gain or loss. As the conversion price was lower than the market share price, the beneficial conversion feature valued at December 31, 2020 of $41,667was allocated to Additional paid-in capital. Subsequently, the fair value of the November 2019 Debenture is accreted over the remaining life of the November 2019 Debenture using an effective rate of interest of 44.9%. Effective May 31, 2021, the maturity date for the November 2019 Debenture was further extended to July 31, 2021. Under ASC Subtopic 470-50, the change in the debt instrument was accounted for as an extinguishment. In accordance with ASC paragraph 470-50-40-2, extinguishment transactions between related entities are treated as capital transactions. At the date of extinguishment, the Company derecognized the carrying amount of convertible debt of $250,000 and recorded the new convertible debt at the fair value of $250,000, resulting in no gain or loss. As the conversion price was lower than the market share price, the beneficial conversion feature valued at May 31, 2021 of $125,000was allocated to Additional paid-in capital. Subsequently, the fair value of the November 2019 Debenture is accreted over the remaining life of the November 2019 Debenture using an effective rate of interest of 496.1%. Effective July 31, 2021, the maturity date for the November 2019 Debenture was further extended to October 31, 2021. Under ASC Subtopic 470-50, the change in the debt instrument was accounted for as an extinguishment. In accordance with ASC paragraph 470-50-40-2, extinguishment transactions between related entities are treated as capital transactions. At the date of extinguishment, the Company derecognized the carrying amount of convertible debt of $250,000 and recorded the new convertible debt at the fair value of $250,000, resulting in no gain or loss. As the conversion price was lower than the market share price, the beneficial conversion feature valued at July 31, 2021 of $125,000was allocated to Additional paid-in capital. Subsequently, the fair value of the November 2019 Debenture is accreted over the remaining life of the November 2019 Debenture using an effective rate of interest of 309.6%. Effective October 31, 2021, the maturity date for the November 2019 Debenture was further extended to February 28, 2022. Under ASC Subtopic 470-50, the change in the debt instrument was accounted for as an extinguishment. In accordance with ASC paragraph 470-50-40-2, extinguishment transactions between related entities are treated as capital transactions. At the date of extinguishment, the Company derecognized the carrying amount of convertible debt of $250,000 and recorded the new convertible debt at the fair value of $250,000, resulting in no gain or loss. As the conversion price was lower than the market share price, the beneficial conversion feature valued at October 31, 2021 of $62,500 was allocated to Additional paid-in capital. Subsequently, the fair value of the November 2019 Debenture is accreted over the remaining life of the November 2019 Debenture using an effective rate of interest of 90.8%. Effective February 28, 2022, the maturity date for the November 2019 Debenture was further extended to May 31, 2022. Under ASC Subtopic 470-50, the change in the debt instrument was accounted for as an extinguishment. In accordance with ASC paragraph 470-50-40-2, extinguishment transactions between related entities are treated as capital transactions. At the date of extinguishment, the Company derecognized the carrying amount of convertible debt of $250,000 and recorded the new convertible debt at the fair value of $250,000, resulting in no gain or loss. As the conversion price was lower than the market share price, the beneficial conversion feature valued at February 28, 2022 of $20,833 was allocated to Additional paid-in capital. Subsequently, the fair value of the November 2019 Debenture is accreted over the remaining life of the November 2019 Debenture using an effective rate of interest of 35.1%. Effective May 31, 2022, the maturity date for the November 2019 Debenture was further extended to November 30, 2022. Under ASC Subtopic 470-50, the change in the debt instrum

Lease

Lease	6 Months Ended
	May 31, 2022
Lease
Lease	6. Lease On December 1, 2015, the Company entered into a new lease agreement for the premises that it currently operates from, as well the adjoining property, which is owned by the same landlord, for a 5-year term with a 5-year renewal option. On June 21, 2020, the Company entered into a lease surrender agreement and vacated one of its premises on June 30, 2020. On December 15, 2021, The Company extended its lease for the premises that it currently operates from, for one year, commencing December 1, 2021, with an option to continue on a month-to-month basis after November 30, 2022. This operating lease was capitalized under ASC Topic 842 Leases effective on the December 1, 2021 date of extension. The gross amounts of assets and liabilities related to operating leases were as follows: May 31, 2022 November 30, 2021 Assets: Operating lease right-of-use asset $ 82,143 $ - Liabilities: Current: Operating lease liability $ 83,185 $ - Total lease liability $ 83,185 $ - Operating lease costs amounted to $87,833 for the six months ended May 31, 2022 (six months ended May 31, 2021 – $40,551) respectively and have been recorded in selling, general and administrative expenses in the condensed unaudited interim consolidated statements of operations and comprehensive loss. For the six months ended May 31, 2021, lease payments of $87,566 were paid in relation to the operating lease liability. Lease terms and discount rates are as follows: May 31, 2022 Remaining lease term (months) 6 Estimated incremental borrowing rate 11.4 % The approximate future minimum lease payments for the operating lease as at May 31, 2022 were as follows: May 31, 2022 Lease payments for the remainder of the year ending November 30, 2021 $ 129,199 Less imputed interest 46,014 Present value of lease liabilities $ 83,185

Capital Stock

Capital Stock	6 Months Ended
	May 31, 2022
Capital Stock
Capital Stock	7. Capital stock Authorized, issued and outstanding (a) (b) Authorized, issued and outstanding price divided by the market price. The March 2018 Warrants and March 2018 Placement Agent Warrants are considered to be indexed to the Company’s own stock and are therefore classified as equity under ASC Topic 480. The Company recorded $4,184,520 as the value of common shares under Capital stock and $1,115,480 as the value of the March 2018 Warrants under Additional paid-in capital in the condensed unaudited interim consolidated statements of shareholders’ equity (deficiency). The Company has disclosed the terms used to value the warrants in Note 10. The direct costs related to the issuance of the common shares and warrants were $831,357 including the cost of warrants issued to the placement agents. These direct costs were recorded as an offset against the condensed unaudited interim consolidated statements of shareholders’ equity (deficiency) with $656,383 being recorded under Capital stock and $174,974 being recorded under Additional paid-in capital. (c) The Company raised $14,344,906 in gross proceeds as part of October 2018 underwritten public offering. The Company recorded $1,808,952 as the value of common shares under Capital stock and $279,086 as the value of the 2018 Firm Warrants and $12,256,868 as the value of the 2018Pre-Funded Warrants under Additional paid-in capital in the condensed unaudited interim consolidated statements of shareholders’ equity (deficiency). The direct costs related to the issuance of the common shares and warrants issued in October 2018 were $2,738,710 including the cost of October 2018 Placement Agent Warrants in the amount of $461,697. These direct costs were recorded as an offset against the condensed unaudited interim consolidated statements of shareholders’ equity (deficiency) with $345,363 being recorded under Capital stock and $2,393,347 being recorded under Additional paid-in capital. In April 2021, the Company completed a private placement offering of an aggregate of 9,414,560 common shares at a price of CAD$0.41 per Common Share. The Company recorded $3,069,448 as the value of common shares under Capital stock in the condensed unaudited interim consolidated statements of shareholders’ equity (deficiency). The direct costs related to the issuance of the common shares were $38,220. These direct costs were recorded as an offset against the condensed unaudited interim consolidated statements of shareholders’ equity (deficiency).

Options

Options	6 Months Ended
	May 31, 2022
Options
Options	8. Options All grants of options to employees after October 22, 2009 are made from the Employee Stock Option Plan (the “Employee Stock Option Plan”). The maximum number of common shares issuable under the Employee Stock Option Plan is limited to 10% of the issued and outstanding common shares of the Company from time to time, or 3,309,267 based on the number of issued and outstanding common shares as at May 31, 2022. As at May 31, 2022, 1,489,500 options are outstanding and there were 1,819,767 options available for grant under the Employee Stock Option Plan. Each option granted allows the holder to purchase one common share at an exercise price not less than the closing price of the Company’s common shares on the TSX on the last trading day prior to the grant of the option. Options granted under these plans typically have a term of 5 years with a maximum term of 10 years and generally vest over a period of up to three years. In August 2004, the Board of Directors of IPC Ltd. approved a grant of 276,394 performance-based stock options, to two executives who were also the principal shareholders of IPC Ltd. The vesting of these options is contingent upon the achievement of certain performance milestones. A total of 276,394 performance-based stock options have vested as of May 31, 2020. Under the terms of the original agreement these options were to expire in September 2014. Effective March 27, 2014, the Company’s shareholders approved the two-year extension of the performance-based stock option expiry date to September 2016. Effective April 19, 2016, the Company’s shareholders approved a further two-year extension of the performance-based stock option expiry date to September 2018. Effective May 15, 2018, the Company’s shareholders approved a further two-year extension of the performance-based stock option expiry date to September 2020. As of November 30, 2020, these options have expired. In the three and six months ended May 31, 2022, Nil (three and six months ended May 31, 2021 –- Nil) stock options were granted. The fair value of each option grant is estimated on the date of grant using the Black-Scholes Option-Pricing Model, consistent with the provisions of ASC Topic 718 Option pricing models require the use of subjective assumptions, changes in these assumptions can materially affect the fair value of the options. The Company calculates expected volatility based on historical volatility of the Company’s own volatility for options that have an expected life of less than ten years. The expected term, which represents the period of time that options granted are expected to be outstanding, is estimated based on the historical average of the term and historical exercises of the options. The risk-free rate assumed in valuing the options is based on the U.S. treasury yield curve in effect at the time of grant for the expected term of the option. The expected dividend yield percentage at the date of grant is Nil as the Company is not expected to pay dividends in the foreseeable future. Details of stock option transactions in Canadian dollars (“C$”) are as follows: May 31, 2022 May 31, 2021 Weighted Weighted average Weighted average Weighted exercise average exercise average Number of price per grant date Number of price per grant date options share fair value options share fair value # $ $ # $ $ Outstanding, beginning of period 1,489,500 2.40 1.80 1,697,638 2.92 1.99 Expired (85,000 ) 32.70 25.08 - - - Cancelled - - - (142,737 ) 1.07 0.58 Balance at end of period 1,404,500 0.55 0.38 1,554,901 3.09 2.12 Options exercisable end of period 1,404,500 0.55 0.38 1,554,901 3.09 2.12 Total unrecognized compensation cost relating to the unvested performance-based stock options at May 31, 2022 is $Nil (May 31, 2021 - $Nil). For the three and six months ended May 31, 2022 and 2020, no options were exercised. The following table summarizes the components of stock-based compensation expense. Three months ended Six months ended Stock-based compensation related to: May 31, 2022 May 31, 2021 May 31, 2022 May 31, 2021 Research and development - 1,127 - 9,719 Selling, general and administrative - 308 - 2,266 - 1,435 - 11,985 The Company has estimated its stock option forfeitures to be approximately 4% for the three and six months ended May 31, 2021 (three and six months ended May 31, 2020 – 4%).

Deferred Share Units

Deferred Share Units	6 Months Ended
	May 31, 2022
Deferred Share Units
Deferred Share Units	9. Deferred share units Effective May 28, 2010, the Company’s shareholders approved a Deferred Share Unit (“DSU”) Plan to grant DSUs to its non-management directors and reserved a maximum of 11,000 common shares for issuance under the plan. The DSU Plan permits certain non-management directors to defer receipt of all or a portion of their board fees until termination of the board service and to receive such fees in the form of common shares at that time. A DSU is a unit equivalent in value to one common share of the Company based on the trading price of the Company’s common shares on the TSX. Upon termination of board service, the director will be able to redeem DSUs based upon the then market price of the Company’s common shares on the date of redemption in exchange for any combination of cash or common shares as the Company may determine. During the three and six months ended May 31, 2022, no non-management board members elected to receive director fees in the form of DSUs under the Company’s DSU Plans. As at May 31, 2022, Nil (May 31, 2021 Nil) DSUs were outstanding and 11,000 (May 31, 2021 – 11,000) DSUs were available for grant under the DSU Plan. During the three and six months ended May 31, 2022 and 2021, no DSUs were exercised.

Warrants

Warrants	6 Months Ended
	May 31, 2022
Warrants
Warrants	10. Warrants All of the Company’s outstanding warrants are considered to be indexed to the Company’s own stock and are therefore classified as equity under ASC 480 Distinguishing Liabilities from Equity. The warrants, in specified situations, provide for certain compensation remedies to a holder if the Company fails to timely deliver the shares underlying the warrants in accordance with the warrant terms. In the underwritten public offering completed in June 2016, gross proceeds of $5,200,000 were received through the sale of the Company’s units comprised of common shares and warrants. The Company issued at the initial closing of the offering an aggregate of 322,981 common shares and warrants to purchase an additional 161,490 common shares, at a price of $16.10 per unit. The warrants are currently exercisable, have a term of five years and an exercise price of $19.30 per common share. The underwriter also purchased at such closing additional warrants (collectively with the warrants issued at the initial closing, the “June 2016 Warrants”) at a purchase price of $0.01 per warrant to acquire 24,223 common shares pursuant to the overallotment option exercised in part by the underwriter. The fair value of the June 2016 Warrants of $1,175,190 was initially estimated at closing using the Black-Scholes Option Pricing Model, using volatility of 64.1%, risk free interest rate of 0.92%, expected life of 5 years, and dividend yield of Nil. The June 2016 Warrants currently outstanding are detailed below. In the registered direct offering completed in October 2017, gross proceeds of $4,000,000 were received through the sale of the Company’s common shares and warrants. The Company issued at the closing of the offering an aggregate of 363,636 common shares at a price of $11.00 per share and warrants to purchase an additional 181,818 common shares (the “October 2017 Warrants”). The October 2017 Warrants became exercisable six months following the closing date, will expire 30 months after the date they became exercisable, and have an exercise price of $12.50 per common share. The Company also issued the October 2017 Placement Agents Warrants to purchase 18,181 common shares at an exercise price of $13.75 per share. The holders of October 2017 Warrants and October 2017 Placement Agent Warrants are entitled to a cashless exercise under which the number of shares to be issued will be based on the number of shares for which warrants are exercised times the difference between the market price of the common share and the exercise price divided by the market price. The fair value of the October 2017 Warrants of $742,555 was initially estimated at closing using the Black-Scholes Option Pricing Model, using volatility of 73.67%, risk free interest rate of 1.64%, expected life of 3 years, and dividend yield of Nil. The fair value of the October 2017 Placement Agents Warrants was estimated at $86,196 using the Black-Scholes Option Pricing Model, using volatility of 73.67%, a risk-free interest rate of 1.64%, an expected life of 3 years, and a dividend yield of Nil. The October 2017 Warrants and the October 2017 Placement Agent Warrants currently outstanding are detailed below. In the two registered direct offerings completed in March 2018, gross proceeds of $5,300,000 were received through the sale of the Company’s common shares and warrants. The Company issued at the closing of the offering an aggregate of 883,333 common shares at a price of $6.00 per share and the March 2018 Warrants to purchase an additional 441,666 common shares. The March 2018 Warrants became exercisable six months following the closing date, will expire 30 months after the date they became exercisable and have an exercise price of $6.00 per common share. The Company also issued the March 2018 Placement Agent Warrants to purchase 44,166 common shares at an exercise price of $7.50 per share. The holders of March 2018 Warrants and March 2018 Placement Agent Warrants are entitled to a cashless exercise under which the number of shares to be issued will be based on the number of shares for which warrants are exercised times the difference between the market price of the common share and the exercise price divided by the market price. The fair value of the March 2018 Warrants of $1,115,480 was initially estimated at closing using the Black-Scholes Option Pricing Model, using volatility of 70%, risk free interest rates of 2.44% and 2.46%, expected life of 3 years, and dividend yield of Nil. The fair value of the March 2018 Placement Agent Warrants was estimated at $141,284 using the Black-Scholes Option Pricing Model, using volatility of 70%, risk free interest rates of 2.44% and 2.46%, an expected life of 3 years, and a dividend yield of Nil. The March 2018 Warrants and the March 2018 Placement Agent Warrants currently outstanding are detailed below. In October 2018, the Company completed an underwritten public offering in the United States, resulting in the sale to the public of 827,970 Units at $0.75 per Unit, which are comprised of one common share and one 2018 Unit Warrant (as defined above) exercisable at $0.75 per share. The Company concurrently sold an additional 1,947,261 common shares and 2018 Option Warrants to purchase 2,608,695 common shares exercisable at $0.75 per share pursuant to the overallotment option exercised in part by the underwriter. The price of the common shares issued in connection with exercise of the overallotment option was $0.74 per share and the price for the warrants issued in connection with the exercise of the overallotment option was $0.01 per warrant, less in each case the underwriting discount. In addition, the Company issued 16,563,335 2018 Pre-Funded Units (as defined above), each 2018 Pre-Funded Unit consisting of one 2018 Pre-Funded Warrant (as defined above) to purchase one common share and one 2018 Warrant (as defined above) to purchase one common share. The 2018 Pre-Funded Units were offered to the public at $0.74 each and a 2018 Pre-Funded Warrant is exercisable at $0.01 per share. Each 2018 Firm Warrant is exercisable immediately and has a term of five years and each 2018 Pre-Funded Warrant is exercisable immediately and until all 2018 Pre-Funded Warrants are exercised. The Company also issued the October 2018 Placement Agent Warrants to the placement agents to purchase 1,160,314 common shares at an exercise price of $0.9375 per share, which were exercisable immediately upon issuance. In aggregate, in October 2018, the Company issued 2,775,231 common shares, 16,563,335 2018 Pre-Funded Warrants and 20,000,000 2018 Firm Warrants in addition to 1,160,314 October 2018 Placement Agent Warrants. The fair value of the 2018 Firm Warrants of $279,086 was initially estimated at closing using the Black-Scholes Option Pricing Model, using volatility of 92%, risk free interest rate of 3.02%, expected life of 5 years, and dividend yield of Nil. The fair value of the October 2018 Placement Agents Warrants was estimated at $461,697 using the Black-Scholes Option Pricing Model, using volatility of 92%, risk free interest rate of 3.02%, an expected life of 5 years, and a dividend yield of Nil. The fair value of the 2018 Pre-Funded Warrant of $12,256,868 and the fair value of the 2018 Firm Warrants of $279,086, respectively, were recorded under Additional paid-in capital in the condensed unaudited interim consolidated statements of shareholders’ equity (deficiency). The following table provides information on the 21,160,314 warrants including 2018 Firm Warrants outstanding and exercisable as of May 31, 2022: Exercise Number Shares issuable Warrant price ($) outstanding Expiry upon exercise 2018 Firm Warrants 0.75 20,000,000 October 16, 2023 20,000,000 October 2018 Placement Agent Warrants 0.9375 1,160,314 October 16, 2023 1,160,314 21,160,314 21,160,314 During the three and six months ended May 31, 2022, there were no cash exercises in respect of warrants (three and six months ended May 31, 2021 – Nil). Details of warrant transactions for the six months ended May 31, 2021 and 2020 are as follows: Outstanding, December 1, 2021 Issued Expired Exercised Outstanding, May 31, 2022 2018 Firm Warrants 20,000,000 - - - 20,000,000 October 2018 Placement Agent Warrants 1,160,314 - - - 1,160,314 21,160,314 - - - 21,160,314 Outstanding, December 1, 2020 Issued Expired Exercised Outstanding, May 31, 2021 June 2016 Warrants 277,478 - - - 277,478 March 2018 Warrants 441,666 - (441,666 ) - - March 2018 Placement Agent Warrants 44,166 - (44,166 ) - - 2018 Firm Warrants 20,000,000 - - - 20,000,000 October 2018 Placement Agent Warrants 1,160,314 - - - 1,160,314 21,923,624 - (485,832 ) - 21,437,792

Income Taxes

Income Taxes	6 Months Ended
	May 31, 2022
Income Taxes
Income Taxes	11 Income taxes The Company has had no taxable income under the Federal and Provincial tax laws of Canada for the three and six months ended May 31, 2022 and May 31, 2021. The Company has non-capital loss carry-forwards at May 31, 2022 in Canada $62,427,238 that must be offset against future taxable income. If not utilized, the loss carry-forwards will expire between 2028 and 2042. For the three and six months ended May 31, 2022, the Company had a cumulative carry-forward pool of Canadian Federal Scientific Research & Experimental Development expenditures in the amount of approximately $15,951,739, which can be carried forward indefinitely. For the three and six months ended May 31, 2022, the Company had approximately $2,933,013 of unclaimed Investment Tax Credits which expire from 2025 to 2040. These credits are subject to a full valuation allowance as they are not more likely than not to be realized.

Contingencies

Contingencies	6 Months Ended
	May 31, 2022
Contingencies (Note 12)
Contingencies	12. Contingencies From time to time, the Company may be exposed to claims and legal actions in the normal course of business. As at May 31, 2022, and continuing as at July 21, 2022, the Company is not aware of any pending or threatened material litigation claims against the Company, other than as described below. In November 2016, the Company filed an NDA for its abuse-deterrent oxycodone hydrochloride extended release tablets (formerly referred to as Rexista TM ® On April 7, 2017, the Company received notice that Purdue Pharma L.P., Purdue Pharmaceuticals L.P., The P.F. Laboratories, Inc., or collectively the Purdue parties, Rhodes Technologies, and Grünenthal GmbH, or collectively the Purdue litigation plaintiffs, had commenced patent infringement proceedings against the Company in the U.S. District Court for the District of Delaware (docket number 17-392) in respect of its NDA filing for Oxycodone ER, alleging that its proposed Oxycodone ER infringes six out of the 16 patents associated with the branded product OxyContin ® ® Subsequent to the above-noted filing of lawsuit, four further such patents were listed and published in the Orange Book. On March 16, 2018, the Company received notice that the Purdue litigation plaintiffs had commenced further such patent infringement proceedings adding the four further patents. On April 15, 2020, Purdue filed a new patent infringement suit against the Company relating to additional Paragraph IV certifications lodged against two more listed Purdue patents. As a result of the commencement of the first of these legal proceedings, the FDA was stayed for 30 months from granting final approval to the Company’s Oxycodone ER product candidate. That time period commenced on February 24, 2017, when the Purdue litigation plaintiffs received notice of the Company’s certification concerning the patents, and were to expire on August 24, 2019, unless the stay was earlier terminated by a final declaration of the courts that the patents are invalid, or are not infringed, or the matter is otherwise settled among the parties. On April 24, 2019, an order was issued, setting a trial date of November 12, 2019 for case number 17-392 in the District of Delaware, and also extending the 30-month stay date for regulatory approval to March 2, 2020. On or about June 26, 2018, the court issued an order to sever 6 “overlapping” patents from the second Purdue case, but ordered litigation to proceed on the 4 new (2017-issued) patents. An answer and counterclaim was filed on July 9, 2018. On July 6, 2018, the court issued a so-called “Markman” claim construction ruling on the first case. On July 24, 2018, the parties to the case mutually agreed to and did have dismissed without prejudice the infringement claims related to the Grünenthal ‘060 patent, which is one of the six patents included in the original litigation case. On October 4, 2018, the parties mutually agreed to postpone the scheduled court date pending a case status conference scheduled for December 17, 2018. At that time, further trial scheduling and other administrative matters were postponed pending the Company’s resubmission of the Oxycodone ER NDA to the FDA, which was made on February 28, 2019. On January 17, 2019, the court issued a scheduling order in which the remaining major portions are scheduled. The trial was scheduled for June 2020. On April 4, 2019, the U.S. Federal Circuit Court of Appeals affirmed the invalidity of one Purdue OxyContin® formulation patent, subject to further appeal to the U.S. Supreme Court. Following the filing of a bankruptcy stay by Purdue Pharma L.P., the Company’s ongoing litigation case numbers 1:17-cv-00392-RGA and 1:18-cv-00404-RGA-SRF between Purdue Pharma L.P. et al and The Company were stayed and the existing trial dates in both cases vacated by orders issued in each case by the judge in the District of Delaware on October 3, 2019. With the litigation stay order, the previous 30-month stay date of March 2, 2020 was unchanged. On or about July 2, 2020 the parties in the cases, numbers 17-cv-392-RGA, 18-cv-404-RGA and 20-cv-515-RGA (the “Litigations”) between Purdue Pharma L.P. et al (“Purdue’) and Intellipharmaceutics entered into a stipulated dismissal of the Litigations. The stipulated dismissal, which was subject to approval by the bankruptcy court presiding over Purdue Pharma’s pending chapter 11 cases, provides for the termination of the patent infringement proceedings. The stipulated dismissal also provides that (i) for a thirty (30) day period following a final approval of the Company’s Aximris XR TM On July 28, 2020 the U.S. District Court for the District of Delaware signed the stipulations of dismissal into order thereby dismissing the claims in the three cases without prejudice. In consideration of the confidential stipulated dismissal agreement and for future saved litigation expenses, Purdue paid an amount to the Company. In July 2017, three complaints were filed in the U.S. District Court for the Southern District of New York that were later consolidated under the caption Shanawaz v. Intellipharmaceutics Int’l Inc., et al., No. 1:17-cv-05761 (S.D.N.Y.) In an order entered at the parties’ request on May 9, 2019, the Court stayed proceedings in the action to permit the parties time to conduct a mediation. As a result of subsequent extensions, the stay was extended through October 10, 2019. The parties participated in a mediation on August 1, 2019, during which the parties tentatively agreed to the terms of a settlement of the action subject to the satisfaction of certain financial conditions by the Company. On November 7, 2019, the Company announced that the parties reached a settlement that is subject to the approval of the court following notice to class members. The stipulation of settlement provides for a settlement payment of US$1.6 million by the Company, which has been paid from available insurance coverage. As part of the settlement, the Company also agreed to contribute to the settlement fund specific anticipated Canadian tax refunds of up to US$400,000 to the extent received within 18 months after the entry of final judgment. The stipulation of settlement acknowledges that the Company and the other defendants continue to deny that they committed any violation of the U.S. securities laws or engaged in any other wrongdoing and that they are entering into the settlement at this time based on the burden, expense, and inherent uncertainty of continuing the litigation.On December 7, 2020 the court approved the settlement and entered an order and final judgement to that effect, thereby concluding the case. On February 21, 2019, the Company and its CEO, Dr. Isa Odidi (“Defendants”), were served with a Statement of Claim filed in the Superior Court of Justice of Ontario (“Court”) for a proposed class action under the Ontario Class Proceedings Act (“Action”). The Action was brought by Victor Romita, the proposed representative plaintiff (“Plaintiff”), on behalf of a class of Canadian persons (“Class”) who traded shares of the Company during the period from February 29, 2016 to July 26, 2017 (“Period”). The Statement of Claim, under the caption Victor Romita v. Intellipharmaceutics International Inc. and Isa Odidi the Court, in accordance with procedure under the Ontario Securities Act, to allow the statutory claims under the Ontario Securities Act to proceed with respect to the claims based upon the acquisition or disposition of the Company’s shares on the TSX during the Period (“Motion”). On June 28, 2019, the Court endorsed a timetable for the exchange of material leading to the hearing of the Motion scheduled for January 27-28, 2020. On October 28, 2019, plaintiff’s counsel advised the court that the Plaintiff intended to amend his claim and could not proceed with the Leave Motion scheduled for January 27-28, 2020. As such, the Court released those dates. On January 28, 2020 the plaintiff served a Notice of Motion for leave to amend the Statement of Claim. On April 2, 2020 the plaintiff delivered an Amended Motion Record and Amended Notice of Motion seeking an order for leave to issue a fresh as Amended Statement of Claim including the addition of Christopher Pearce as a Plaintiff (“Amendment Motion”). On May 1, 2020, the court granted the plaintiff’s Amendment Motion. An order for leave to proceed for settlement purposes was granted on 25 June 2021.A tentative settlement was reached in this case. An order for leave to proceed for settlement purposes was granted by the judge on June 25, 2021. At a hearing on October 12, 2021, the Court approved the settlement. The amount of CAD$266,000 provided by the stipulation of settlement has been paid; CAD$226,000 was paid from insurance coverage while the Company paid CAD$40,000. On October 7, 2019, a complaint was filed in the U.S. District Court for the Southern District of New York by Alpha Capital Anstalt (“Alpha”) against the Company, two of its existing officers and directors and its former Chief Financial Officer. In the complaint, Alpha alleges that the Company and the executive officers/directors named in the complaint violated Sections 11, 12(a)(2) and 15 of the U.S. Securities Act of 1933, as amended, by allegedly making false and misleading statements in the Company’s Registration Statement on Form F-1 filed with the U.S. Securities and Exchange Commission on September 20, 2018, as amended (the “Registration Statement”) by failing to disclose certain information regarding the resignation of the Company’s then Chief Financial Officer, which was announced several weeks after such registration statement was declared effective. In the complaint, Alpha seeks unspecified damages, rescission of its purchase of the Company’s securities in the relevant offering, attorneys’ fees and other costs and further relief as the court may find just and proper. On December 12, 2019, the Company and the other defendants in the action filed a motion to dismiss for failure to state a claim. The plaintiff filed an opposition to that motion on February 4, 2020 and a reply brief in further support of the motion to dismiss the action was filed March 6, 2020. In addition, the Court scheduled a mandatory settlement conference with the Magistrate Judge for April 23, 2020 which the Company and its counsel attended. On June 18, 2020, the court largely denied the Company’s motion to dismiss the action. Briefing on these motions was completed on February 19, 2021.In a court order filed July 9, 2021, the District Court issued an opinion and order granting summary judgment in the Company’s favor and ordered the case closed. The judgment was entered on July 12, 2021. On August 10, 2021, the Plaintiff filed a notice of appeal. On October 1, 2021, the Plaintiff filed a notice of voluntary dismissal of the appeal with prejudice, stipulated to by the Company. The Court of Appeals “so ordered” the voluntary dismissal stipulation and the appeal was dismissed. As a result, the matter has been fully resolved in favor of the Company and the named individual Defendants. On or about August 5, 2020 a former employee filed a claim against the Company for wrongful dismissal of employment plus loss of benefits, unpaid vacation pay, interest and costs. The parties have agreed to settlement terms in the matter.

Financial Instruments

Financial Instruments	6 Months Ended
	May 31, 2022
Financial Instruments
Financial Instruments	13. Financial instruments (a) Fair values The Company follows ASC Topic 820 Fair Value Measurement (“ASC Topic 820”), which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. The provisions of ASC Topic 820 apply to other accounting pronouncements that require or permit fair value measurements. ASC Topic 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date; and establishes a three-level hierarchy for fair value measurements based upon the transparency of inputs to the valuation of an asset or liability as of the measurement date. Inputs refer broadly to the assumptions that market participants would use in pricing the asset or liability, including assumptions about risk. To increase consistency and comparability in fair value measurements and related disclosures, the fair value hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The three levels of the hierarchy are defined as follows: Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs for asset or liabilities. The categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. (i) The Company calculates fair value of the options and warrants using its own historical volatility (Level 1). (ii) The Company calculates the interest rate for the conversion option based on the Company’s estimated cost of raising capital (Level 2). An increase/decrease in the volatility and/or a decrease/increase in the discount rate would have resulted in an increase/decrease in the fair value of the conversion option and warrants. Fair value of financial assets and financial liabilities that are not measured at fair value on a recurring basis are as follows: May 31, 2022 November 30, 2021 Carrying Fair Carrying Fair amount value amount value $ $ $ $ Financial Liabilities Convertible debentures (i) 1,800,000 1,766,498 1,751,483 1,783,882 Promissory notes payable (i) 167,693 167,693 165,878 165,878 (I) The Company calculates the interest rate for the Debentures and promissory notes payable based on the Company’s estimated cost of raising capital and uses the discounted cash flow model to calculate the fair value of the Debentures and the promissory notes payable. The carrying values of cash, accounts receivable, accounts payable, accrued liabilities and employee cost payable approximates their fair values because of the short-term nature of these instruments. (b) Interest rate and credit risk Interest rate risk is the risk that the value of a financial instrument might be adversely affected by a change in interest rates. The Company does not believe that the results of operations or cash flows would be affected to any significant degree by a sudden change in market interest rates, relative to interest rates on cash and the convertible debenture due to the short-term nature of these obligations. Trade accounts receivable potentially subjects the Company to credit risk. The Company provides an allowance for doubtful accounts equal to the estimated losses expected to be incurred in the collection of accounts receivable. Financial instruments that potentially subject the Company to concentration of credit risk consist principally of uncollateralized accounts receivable. The Company’s maximum exposure to credit risk is equal to the potential amount of financial assets. On July 2, 2020, the Company reached a stipulated dismissal agreement with regards to all three cases in the litigation between Purdue and the Company. In consideration of the confidential dismissal agreement and for future saved litigation expenses, Purdue paid $2,000,000 to the Company and paid an additional $500,000 in December 2020. During the year ended November 30, 2020, the Company received the initial payment of $2,000,000 and the remaining $500,000 was recognized as other receivable within trade and other receivables in the Company’s consolidated balance sheet as at November 30, 2020. The Company is also exposed to credit risk at period end from the carrying value of its cash. The Company manages this risk by maintaining bank accounts with a Canadian Chartered Bank. The Company’s cash is not subject to any external restrictions. (c) Foreign exchange risk The Company has balances in Canadian dollars that give rise to exposure to foreign exchange risk relating to the impact of translating certain non-U.S. dollar balance sheet accounts as these statements are presented in U.S. dollars. A strengthening U.S. dollar will lead to a foreign exchange loss while a weakening U.S. dollar will lead to a foreign exchange gain. For each Canadian dollar balance of $1.0 million, a +/- 10% movement in the Canadian currency held by the Company versus the U.S. dollar would affect the Company’s loss and other comprehensive loss by $0.1 million. (d) Liquidity risk Liquidity risk is the risk that the Company will encounter difficulty raising liquid funds to meet its commitments as they fall due. In meeting its liquidity requirements, the Company closely monitors its forecasted cash requirements with expected cash drawdown. The following are the contractual maturities of the undiscounted cash flows of financial liabilities as at May 31, 2022: Less than 3 to 6 6 to 9 9 months Greater than 3 months months months to 1 year 1 year Total $ $ $ $ $ $ Accounts payable 4,285,339 - - - - 4,285,339 Accrued liabilities 2,712,045 - - - - 2,712,045 Employee costs payable 2,671,154 - - - - 2,671,154 Operating lease liability (Note 6) 43,066 43,066 - - - 86,132 Convertible debentures (Note 5) 1,800,000 - - - - 1,800,000 Promissory notes payable (Note 5) 167,693 - - - - 167,693 Total contractual obligations 11,679,297 43,066 - - - 11,722,363

Segmented Information

Segmented Information	6 Months Ended
	May 31, 2022
Segmented Information
Segmented Information	14 . Segmented information The Company’s operations comprise a single reportable segment engaged in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. As the operations comprise a single reportable segment, amounts disclosed in the financial statements for revenue, loss for the period, depreciation and total assets also represent segmented amounts. In addition, all of the Company’s long-lived assets are in Canada. The Company’s license and commercialization agreement with Par accounts for substantially all of the revenue of the Company. Three months ended Six months ended May 31, May 31, May 31, May 31, 2022 2021 2022 2021 $ $ $ $ Revenue United States - 93,427 16,978 93,427 May 31, November 30, 2022 2021 $ $ Total assets Canada 1,881,583 2,096,425 Total property and equipment Canada 891,153 994,109 For the three months ended February 28, February 28, 2022 2021 Revenue United States 66,433 - Canada 16,978 - As at February 28, November 30, 2022 2021 Total assets Canada 1,889,571 2,096,425 Total property and equipment Canada 942,631 994,109

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	6 Months Ended
	May 31, 2022
Significant Accounting Policies
Revenue recognition	The Company accounts for revenue in accordance with the provisions of ASC Topic 606 Revenue from Contracts with Customers (“ASC Topic 606”). Under ASC Topic 606, the Company recognizes revenue when the customer obtains control of promised goods or services, in an amount that reflects the consideration the Company expects to receive in exchange for those goods or services. The Company recognizes revenue following the five-step model prescribed under ASC Topic 606: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) the Company satisfies the performance obligation(s). The Company earns revenue from non-refundable upfront fees, milestone payments upon achievement of specified research or development, exclusivity milestone payments and licensing payments on sales of resulting products. The relevant revenue recognition accounting policy is applied to each separate unit of accounting. Licensing The Company recognizes revenue from the licensing of the Company’s drug delivery technologies, products and product candidates. Under the terms of the licensing arrangements, the Company provides the customer with a right to access the Company’s intellectual property with regards to the license which is granted. Revenue arising from the license of intellectual property rights is recognized over the period the Company transfers control of the intellectual property. The Company has a license and commercialization agreement with Par Pharmaceutical Inc. (“Par”). Under the exclusive territorial license rights granted to Par, the agreement requires that Par manufacture, promote, market, sell and distribute the product. Licensing revenue amounts receivable by the Company under this agreement are calculated and reported to the Company by Par, with amounts generally based upon net product sales and net profit which include estimates for chargebacks, rebates, product returns, and other adjustments. Licensing revenue payments received by the Company from Par under this agreement are not subject to further deductions for chargebacks, rebates, product returns, and other pricing adjustments. Based on this arrangement and the guidance per ASC Topic 606, the Company records licensing revenue over the period the Company transfers control of the intellectual property in the condensed unaudited interim consolidated statements of operations and comprehensive loss. The Company also had a license and commercial supply agreement with Mallinckrodt LLC (“Mallinckrodt”) which provided Mallinckrodt an exclusive license to market, sell and distribute in the U.S. three drug product candidates for which the Company had ANDAs filed with the FDA, one of which (the Company’s generic Seroquel XR®) received final approval from the FDA in 2017. Under the terms of this agreement, the Company was responsible for the manufacture of approved products for subsequent sale by Mallinckrodt in the U.S. market. Following receipt of final FDA approval for its generic Seroquel XR®, the Company began shipment of manufactured product to Mallinckrodt. The Company recorded revenue once Mallinckrodt obtained control of the product and the performance obligation was satisfied. Milestones For milestone payments that are not contingent on sales-based thresholds, the Company applies a most-likely amount approach on a contract-by-contract basis. Management makes an assessment of the amount of revenue expected to be received based on the probability of the milestone outcome. Variable consideration is included in revenue only to the extent that it is probable that the amount will not be subject to a significant reversal when the uncertainty is resolved (generally when the milestone outcome is satisfied). Research and development Under arrangements where the license fees and research and development activities can be accounted for as a separate unit of accounting, non-refundable upfront license fees are deferred and recognized as revenue on a straight-line basis over the expected term of the Company’s continued involvement in the research and development process. Deferred revenue Deferred revenue represents the funds received from clients, for which the revenues have not yet been earned, as the milestones have not been achieved, or in the case of upfront fees for drug development, where the work remains to be completed.
Research and development costs	Research and development costs related to continued research and development programs are expensed as incurred in accordance with ASC Topic 730 Research and Development. However, materials and equipment are capitalized and amortized over their useful lives if they have alternative future uses.
Inventory	Inventories comprise of raw materials, work in process, and finished goods, which are valued at the lower of cost or market, on a first-in, first-out basis. Cost for work in process and finished goods inventories includes materials, direct labor, and an allocation of manufacturing overhead. Market for raw materials is replacement cost, and for work in process and finished goods is net realizable value. The Company evaluates the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared with quantities on hand, the price the Company expects to obtain for products in their respective markets compared with historical cost and the remaining shelf life of goods on hand. The recoverability of the cost of any pre-launch inventories with a limited shelf life is evaluated based on the specific facts and circumstances surrounding the timing of the anticipated product launch.
Translation of foreign currencies	Transactions denominated in currencies other than the Company and its wholly owned operating subsidiaries’ functional currencies, monetary assets and liabilities are translated at the period end rates. Revenue and expenses are translated at rates of exchange prevailing on the transaction dates. All of the exchange gains or losses resulting from these other transactions are recognized in the condensed unaudited interim consolidated statements of operations and comprehensive loss. The functional and reporting currency of the Company and its subsidiaries is the U.S. dollar.
Convertible debentures	On September 10, 2018, the Company completed a private placement financing (the “2018 Debenture Financing”) of an unsecured convertible debenture in the principal amount of $500,000 (the “2018 Debenture”). At issuance, the conversion price was lower than the market share price, and the value of the beneficial conversion feature related to the 2018 Debenture was allocated to Additional paid-in capital in the condensed unaudited interim consolidated statements of shareholders’ equity (deficiency). On April 4, 2019, a tentative approval from TSX was received for a proposed refinancing of the 2013 Debenture subject to certain conditions being met. As a result of the refinancing, the principal amount owing under the 2013 Debenture was refinanced by a new debenture (the “May 2019 Debenture”). On May 1, 2019, the May 2019 Debenture was issued in the principal amount of $1,050,000, that was originally scheduled to mature on November 1, 2019, bears interest at a rate of 12% per annum and is convertible into 1,779,661 common shares of the Company at a conversion price of $0.59 per common share. At issuance, the conversion option was not characterized as an embedded derivative as it did not meet the criteria of ASC Topic 815, Derivatives and Hedging On November 15, 2019, the Company issued an unsecured convertible debenture in the principal amount of $250,000 (the “November 2019 Debenture”) that was originally scheduled to mature on December 31, 2019, bears interest at a rate of 12% per annum and is convertible into common shares of the Company at a conversion price of $0.12 per share. At issuance, the conversion price was lower than the market share price, and the value of the beneficial conversion feature related to the November 2019 Debenture was allocated to Additional paid-in capital in the condensed unaudited interim consolidated statements of shareholders’ equity (deficiency).
Investment tax credits	The investment tax credits (“ITC”) receivable are amounts considered recoverable from the Canadian federal and provincial governments under the Scientific Research & Experimental Development (“SR&ED”) incentive program. The amounts claimed under the program represent the amounts based on management estimates of eligible research and development costs incurred during the year. Realization is subject to government approval. Any adjustment to the amounts claimed will be recognized in the year in which the adjustment occurs. Refundable ITCs claimed relating to capital expenditures are credited to property and equipment. Refundable ITCs claimed relating to current expenditures are netted against research and development expenditures.
Loss per share	Basic loss per share (“EPS”) is computed by dividing the loss attributable to common shareholders by the weighted average number of common shares outstanding. Diluted EPS reflects the potential dilution that could occur from common shares issuable through the exercise or conversion of stock options, restricted stock awards, warrants and convertible securities. In certain circumstances, the conversion of options, warrants and convertible securities are excluded from diluted EPS if the effect of such inclusion would be anti-dilutive. The dilutive effect of stock options is determined using the treasury stock method.

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended
	May 31, 2022
Property and Equipment
Schedule of property and equipment	Computer equipment Computer software Furniture and fixtures Laboratory equipment Leasehold improvements Total $ $ $ $ $ Cost Balance at November 30, 2020 631,334 156,059 172,498 5,576,359 1,441,452 7,977,702 Impairment of asset - - - (514,502 ) - (514,502 ) Balance at November 30, 2021 631,334 156,059 172,498 5,061,857 1,441,452 7,463,200 Balance at May 31, 2022 631,334 156,059 172,498 5,061,857 1,441,452 7,463,200 Accumulated depreciation Balance at November 30, 2020 536,697 152,942 145,614 3,930,860 1,441,452 6,207,565 Depreciation 28,391 1,558 5,377 226,200 - 261,526 Balance at November 30, 2021 565,088 154,500 150,991 4,157,060 1,441,452 6,469,091 Depreciation 9,935 390 2,151 90,480 - 102,956 Balance at May 31, 2022 575,023 154,890 153,142 4,247,540 1,441,452 6,572,047 Net book value at: November 30, 2021 66,246 1,559 21,507 904,797 - 994,109 May 31, 2022 56,311 1,169 19,356 814,317 - 891,153

Convertible Debentures and Pr_2

Convertible Debentures and Promissory Notes Payable (Tables)	6 Months Ended
	May 31, 2022
Convertible debentures and promissory notes payable
Schedule of related party transactions	February 28, November 30, 2022 2021 Convertible debenture payable to two directors and officers of the Company, unsecured, 10% annual interest rate, payable monthly (“2018 Debenture”) $ 500,000 $ 500,000 Convertible debenture payable to two directors and officers of the Company, unsecured, 12% annual interest rate, payable monthly (“May 2019 Debenture”) 1,050,000 1,050,000 Convertible debenture payable to two directors and officers of the Company, unsecured, 12% annual interest rate, payable monthly (“November 2019 Debenture”) 250,000 201,483 $ 1,800,000 $ 1,751,483
Schedule of Promissory notes payable	May 31, November 30, 2022 2021 $ $ Promissory notes payable to two directors and officers of the Company, unsecured, no annual interest rate on the outstanding loan balance 167,693 165,878 167,693 165,878

Lease (Tables)

Lease (Tables)	6 Months Ended
	May 31, 2022
Lease
Schedule of operating lease assets and liabilities	May 31, 2022 November 30, 2021 Assets: Operating lease right-of-use asset $ 82,143 $ - Liabilities: Current: Operating lease liability $ 83,185 $ - Total lease liability $ 83,185 $ -
Schedule of Lease terms and discount rates	May 31, 2022 Remaining lease term (months) 6 Estimated incremental borrowing rate 11.4 %
Schedule of Future minimum lease payments	May 31, 2022 Lease payments for the remainder of the year ending November 30, 2021 $ 129,199 Less imputed interest 46,014 Present value of lease liabilities $ 83,185

Options (Tables)

Options (Tables)	6 Months Ended
	May 31, 2022
Options
Schedule of share-based compensation, stock options, activity	May 31, 2022 May 31, 2021 Weighted Weighted average Weighted average Weighted exercise average exercise average Number of price per grant date Number of price per grant date options share fair value options share fair value # $ $ # $ $ Outstanding, beginning of period 1,489,500 2.40 1.80 1,697,638 2.92 1.99 Expired (85,000 ) 32.70 25.08 - - - Cancelled - - - (142,737 ) 1.07 0.58 Balance at end of period 1,404,500 0.55 0.38 1,554,901 3.09 2.12 Options exercisable end of period 1,404,500 0.55 0.38 1,554,901 3.09 2.12
Schedule of employee service share-based compensation, allocation of recognized period costs	Three months ended Six months ended Stock-based compensation related to: May 31, 2022 May 31, 2021 May 31, 2022 May 31, 2021 Research and development - 1,127 - 9,719 Selling, general and administrative - 308 - 2,266 - 1,435 - 11,985

Warrants (Tables)

Warrants (Tables)	6 Months Ended
	May 31, 2022
Warrants (Tables)
Schedule of stockholders' equity note, warrants or rights	Exercise Number Shares issuable Warrant price ($) outstanding Expiry upon exercise 2018 Firm Warrants 0.75 20,000,000 October 16, 2023 20,000,000 October 2018 Placement Agent Warrants 0.9375 1,160,314 October 16, 2023 1,160,314 21,160,314 21,160,314
Schedule of warrant transactions	Outstanding, December 1, 2021 Issued Expired Exercised Outstanding, May 31, 2022 2018 Firm Warrants 20,000,000 - - - 20,000,000 October 2018 Placement Agent Warrants 1,160,314 - - - 1,160,314 21,160,314 - - - 21,160,314 Outstanding, December 1, 2020 Issued Expired Exercised Outstanding, May 31, 2021 June 2016 Warrants 277,478 - - - 277,478 March 2018 Warrants 441,666 - (441,666 ) - - March 2018 Placement Agent Warrants 44,166 - (44,166 ) - - 2018 Firm Warrants 20,000,000 - - - 20,000,000 October 2018 Placement Agent Warrants 1,160,314 - - - 1,160,314 21,923,624 - (485,832 ) - 21,437,792

Financial Instruments (Tables)

Financial Instruments (Tables)	6 Months Ended
	May 31, 2022
Financial Instruments (Tables)
Schedule of fair value measurements, nonrecurring	May 31, 2022 November 30, 2021 Carrying Fair Carrying Fair amount value amount value $ $ $ $ Financial Liabilities Convertible debentures (i) 1,800,000 1,766,498 1,751,483 1,783,882 Promissory notes payable (i) 167,693 167,693 165,878 165,878
Contractual obligation, fiscal year maturity schedule	Less than 3 to 6 6 to 9 9 months Greater than 3 months months months to 1 year 1 year Total $ $ $ $ $ $ Accounts payable 4,285,339 - - - - 4,285,339 Accrued liabilities 2,712,045 - - - - 2,712,045 Employee costs payable 2,671,154 - - - - 2,671,154 Operating lease liability (Note 6) 43,066 43,066 - - - 86,132 Convertible debentures (Note 5) 1,800,000 - - - - 1,800,000 Promissory notes payable (Note 5) 167,693 - - - - 167,693 Total contractual obligations 11,679,297 43,066 - - - 11,722,363

Segmented Information (Tables)

Segmented Information (Tables)	6 Months Ended
	May 31, 2022
Segmented Information
Schedule of revenue from external customers and long-lived assets, by geographical areas	Three months ended Six months ended May 31, May 31, May 31, May 31, 2022 2021 2022 2021 $ $ $ $ Revenue United States - 93,427 16,978 93,427 May 31, November 30, 2022 2021 $ $ Total assets Canada 1,881,583 2,096,425 Total property and equipment Canada 891,153 994,109 For the three months ended February 28, February 28, 2022 2021 Revenue United States 66,433 - Canada 16,978 - As at February 28, November 30, 2022 2021 Total assets Canada 1,889,571 2,096,425 Total property and equipment Canada 942,631 994,109

Nature of Operations (Details N

Nature of Operations (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	May 31, 2022	May 31, 2021	May 31, 2022	May 31, 2021	Nov. 30, 2021
Nature of Operations
Net loss	$ (840,654)	$ (1,000,184)	$ (1,721,626)	$ (1,924,750)
Accumulated deficit	(103,963,331)		(103,963,331)		$ (102,241,705)
Working capital deficiency	$ (10,829,307)		$ (10,829,307)		$ (9,149,327)

Significant Accounting Polici_3

Significant Accounting Policies (Details Narratives) - USD ($)	Nov. 15, 2019	May 01, 2019	Sep. 10, 2018
Significant Accounting Policies
Debt convertible common shares		1,779,661
Unsecured convertible debt, principal amount	$ 250,000	$ 1,050,000	$ 500,000
Unsecured Convertible debt interest rate	12%	12%
Conversion price per share	$ 0.12	$ 0.59

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	6 Months Ended	12 Months Ended
	May 31, 2022	Nov. 30, 2021
Cost, beginning balance	$ 7,463,200	$ 7,977,702
Impairment of asset		514,502
Cost, ending balance	7,463,200	7,463,200
Accumulated amortization, beginning balance	6,469,091	6,207,565
Depreciation	102,956	261,526
Accumulated amortization, ending balance	6,572,047	6,469,091
Property and equipment, net	891,153	994,109
Computer Software
Cost, beginning balance	156,059	156,059
Impairment of asset		0
Cost, ending balance	156,059	156,059
Accumulated amortization, beginning balance	154,500	152,942
Depreciation	390	1,558
Accumulated amortization, ending balance	154,890	154,500
Property and equipment, net	1,169	1,559
Furniture and Fixtures
Cost, beginning balance	172,498	172,498
Impairment of asset		0
Cost, ending balance	172,498	172,498
Accumulated amortization, beginning balance	150,991	145,614
Depreciation	2,151	5,377
Accumulated amortization, ending balance	153,142	150,991
Property and equipment, net	19,356	21,507
Laboratory Equipment
Cost, beginning balance	5,061,857	5,576,359
Impairment of asset		514,502
Cost, ending balance	5,061,857	5,061,857
Accumulated amortization, beginning balance	4,157,060	3,930,860
Depreciation	90,480	226,200
Accumulated amortization, ending balance	4,247,540	4,157,060
Property and equipment, net	814,317	904,797
Leasehold Improvements
Cost, beginning balance	1,441,452	1,441,452
Impairment of asset		0
Cost, ending balance	1,441,452	1,441,452
Accumulated amortization, beginning balance	1,441,452	1,441,452
Depreciation	0	0
Accumulated amortization, ending balance	1,441,452	1,441,452
Property and equipment, net	0	0
Computer Equipment
Cost, beginning balance	631,334	631,334
Impairment of asset		0
Cost, ending balance	631,334	631,334
Accumulated amortization, beginning balance	565,088	536,697
Depreciation	9,935	28,391
Accumulated amortization, ending balance	575,023	565,088
Property and equipment, net	$ 56,311	$ 66,246

Property and Equipment (Detai_2

Property and Equipment (Details Narrative)	12 Months Ended
	Nov. 30, 2021 USD ($)
Property and Equipment
Write-down of long lived assets	$ 514,502

Convertible Debentures and Pr_3

Convertible Debentures and Promissory Notes Payable (Details) - USD ($)	Feb. 28, 2022	Nov. 30, 2021
Convertible debentures and promissory notes payable
Convertible debenture payable to two directors and officers of the Company, unsecured, 10% annual interest rate, payable monthly ("2018 Debenture")	$ 500,000	$ 500,000
Convertible debenture payable to two directors and officers of the Company, unsecured, 12% annual interest rate, payable monthly ("May 2019 Debenture")	1,050,000	1,050,000
Convertible debenture payable to two directors and officers of the Company, unsecured, 12% annual interest rate, payable monthly ("November 2019 Debenture")	250,000	201,483
Promissory note payable to two directors and officers of the Company, unsecured no annual interest rate on the outstanding loan balance	$ 1,800,000	$ 1,751,483

Convertible Debentures and Pr_4

Convertible Debentures and Promissory Notes Payable (Details 1) - USD ($)	May 31, 2022	Nov. 30, 2021
Promissory notes payable	$ 167,693	$ 165,878
Promissory Notes Payable One [Member]
Promissory notes payable	$ 167,693	$ 165,878

Convertible Debentures and Pr_5

Convertible Debentures and Promissory Notes Payable (Details Narrative) - USD ($)						1 Months Ended			3 Months Ended		6 Months Ended		12 Months Ended
	Apr. 04, 2019	Oct. 02, 2018	Sep. 10, 2018	Dec. 01, 2016	Jan. 10, 2013	Nov. 15, 2019	Aug. 26, 2019	Jun. 29, 2015	May 31, 2022	May 31, 2021	May 31, 2022	May 31, 2021	Nov. 30, 2019	Feb. 28, 2022	Nov. 30, 2021	Oct. 31, 2021	Jul. 31, 2021	Dec. 31, 2020	Nov. 30, 2020	Jul. 15, 2020	Jun. 12, 2020	May 15, 2020	Mar. 31, 2020	Jan. 31, 2020	Dec. 31, 2019	Nov. 01, 2019	Sep. 30, 2019	Apr. 01, 2019	Oct. 01, 2018	Sep. 28, 2017	Mar. 28, 2017	May 26, 2016	Dec. 08, 2015	Oct. 01, 2014
Accrued interest expense									$ 20,834	$ 26,278	$ 69,351	$ 49,882
Interest expense									51,888	$ 51,888	102,648	$ 102,648
Convertible debt fair value			$ 500,000						1,050,000		1,050,000			$ 1,050,000		$ 1,050,000	$ 1,050,000	$ 1,050,000	$ 500,000	$ 1,050,000	$ 1,050,000	$ 1,050,000	$ 1,050,000	$ 1,050,000	$ 1,050,000	$ 1,050,000		$ 1,050,000	$ 1,350,000
Convertible debt fair value									1,050,000		1,050,000
Debt instrument carryifng value				$ 106,962																									$ 1,350,000	$ 53,227	$ 113,607	$ 19,808	$ 83,101	$ 126,414
Carrying amount of convertible debt			$ 500,000						1,050,000		1,050,000			1,050,000		1,050,000	1,050,000	1,050,000	$ 500,000	1,050,000	1,050,000	1,050,000	1,050,000	1,050,000	$ 1,050,000	$ 1,050,000		$ 1,050,000
Debt instrument interest rate effective			7.30%	26.30%		152.40%	77.10%																		782.70%					4.90%	15.20%	4.20%	6.60%	15%
Principal repayment		$ 300,000		$ 150,000
Additional paid-in capital			$ 66,667			$ 41,667	$ 7,031						$ 88,652												$ 427,119
Interest rate	12%					12%	8%	14.60%
Recognized loss								$ 114,023
Debt principal amount	$ 1,050,000					$ 250,000	$ 140,800
Proceeds from debt						$ 2,500
Debt conversion price						$ 0.12																						$ 0.59
Convertible common shares	1,779,661
Debt issuance costs							15,800
Convertible debenture							$ 8,769		1,800,000		1,800,000				$ 1,751,483
Gain on settlement													$ 4,419
Non-interest bearing promissory notes																											$ 6,500
Private Placement [Member]
Interest rate			10%		12%
Debt principal amount			$ 500,000		$ 15,000
Proceeds from debt			$ 500,000
Debt conversion price			$ 3		$ 30
2018 Debenture [Member]
Carrying amount of convertible debt									500,000		500,000			500,000		500,000	500,000
November 2019 Debenture [Member]
Convertible debt fair value									250,000		250,000			250,000		250,000,000,000	250,000,000,000	250,000,000,000		250,000,000,000	250,000,000,000	250,000,000,000	250,000,000,000	250,000
Carrying amount of convertible debt									$ 250,000		$ 250,000			$ 250,000		$ 250,000,000,000	$ 250,000,000,000	$ 250,000,000,000		$ 250,000,000,000	$ 250,000,000,000	$ 250,000,000,000	$ 250,000,000,000	$ 250,000
Debt instrument interest rate effective									496.10%		496.10%			35.10%		90.80%	309.60%	44.90%		40%	211.40%	260.90%	72.40%	504.40%
Additional paid-in capital									$ 125,000		$ 125,000			$ 20,833		$ 62,500	$ 125,000	$ 41,666		$ 41,667	$ 41,667	$ 41,667	$ 20,833	$ 125,000

Lease (Details)

Lease (Details) - USD ($)	May 31, 2022	Nov. 30, 2021
Lease
Operating lease right-of-use asset	$ 82,143	$ 0
Current operating lease liability	83,185	0
Total lease liability	$ 83,185	$ 0

Lease (Details 1)

Lease (Details 1)	6 Months Ended
	May 31, 2022
Lease
Remaining lease term (months)	6 years
Estimated incremental borrowing rate	11.40%

Lease (Details 2)

Lease (Details 2) - USD ($)	May 31, 2022	Nov. 30, 2021
Lease
Lease payments for the remainder of the year ending	$ 129,199
Less imputed interest	46,014
Present value of lease liabilities	$ 83,185	$ 0

Lease (Details Narrative)

Lease (Details Narrative) - USD ($)	6 Months Ended
	May 31, 2022	May 31, 2021
Lease
Operating lease cost	$ 87,833	$ 40,551
Lease payments		$ 87,566

Capital Stock (Details Narrativ

Capital Stock (Details Narrative)	1 Months Ended				6 Months Ended
	Apr. 30, 2021 USD ($) shares	Aug. 26, 2019 USD ($)	Oct. 31, 2018 USD ($) $ / shares shares	Mar. 31, 2018 $ / shares shares	May 31, 2022 USD ($) shares	Nov. 30, 2021 USD ($) shares	Apr. 30, 2021 $ / shares	Nov. 30, 2020 shares
Common shares, issued					33,092,665	33,092,665		23,678,105
Common shares, outstanding					33,092,665	33,092,665		23,678,105
Private placement offering of an aggregate of common shares	9,414,560
Share issued, price per share | $ / shares							$ 0.41
Private placement offering of an aggregate of common value | $	$ 3,069,448
Prefunded units, issued			16,563,335
Proceeds from issuance or sale of equity | $			$ 14,344,906
Common stock value, issued | $			1,808,952
Stock issuance costs | $	$ 38,220		$ 2,738,710
Issued common shares			2,775,231
Warrants to purchase				44,166
Common stock | $					$ 49,175,630	$ 49,175,630
Issuance cost | $		$ 15,800
Officers and Directors
Common shares, issued					578,131	578,131
Common shares, outstanding					578,131	578,131
Issued common shares				883,333
Noncontrolling interest, ownership percentage by noncontrolling owners					1.70%	1.70%
Common stock price | $ / shares				$ 6
Exercise price, per common share | $ / shares				$ 6
October 2018 Placement Agent Warrants [Member]
Stock issuance costs | $			$ 345,363
Warrants, exercise price | $ / shares			$ 0.9375
Payment of stock issuance costs | $			$ 461,697
Warrants, issued			1,160,314
Number of securities called by warrants or rights			1,160,314
March 2018 Placement Agent Warrants [Member]
Warrants to purchase				441,666
Exercise price, per share | $ / shares				$ 7.50
Common Stock [Member] | Over-Allotment Option [Member]
Share issued, price per share | $ / shares			$ 0.74
Warrant [Member]
Common stock | $					$ 4,184,520
Capital stock | $					1,115,480
Issuance cost | $					831,357
Warrant [Member] | Over-Allotment Option [Member]
Share issued, price per share | $ / shares			0.01
2018 Pre-Funded Units [Member]
Share issued, price per share | $ / shares			$ 0.74
Prefunded units, issued			16,563,335
Additional Paid In Capital [Member]
Stock issuance costs | $			$ 2,393,347
Direct costs | $					174,974
2018 Pre-Funded Warrants [Member]
Warrants, exercise price | $ / shares			$ 0.01
Warrants issued value | $			$ 12,256,868
Capital Units [Member]
Direct costs | $					$ 656,383
2018 Unit Warrants [Member]
Share issued, price per share | $ / shares			$ 0.75
Warrants, exercise price | $ / shares			$ 0.75
Sale of stock			827,970
2018 Firm Warrants [Member]
Warrants, issued			20,000,000
Warrants issued value | $			$ 279,086
2018 Option Warrants [Member]
Warrants to purchase			2,608,695
Additional common stock and Warrants Issued			1,947,261
Exercisable, per share | $ / shares			$ 0.75

Options (Details)

Options (Details) - $ / shares	6 Months Ended
	May 31, 2022	May 31, 2021
Options
Options Outstanding, Beginning of period	1,489,500	1,697,638
Expired	(85,000)	0
Cancelled	0	(142,737)
Options Outstanding, End of period	1,404,500	1,554,901
Options exercisable, end of period	1,404,500	1,554,901
Weighted average exercise price outstanding, Beginning	$ 2.40	$ 2.92
Weighted average exercise price, Expired	32.70	0
Weighted average exercise price, Cancelled	0	1.07
Weighted average exercise price outstanding, Ending	0.55	3.09
Weighted average exercise price, Options exercisable end of period	0.55	3.09
Weighted average grant date fair value, Beginning	1.80	1.99
Weighted average grant date fair value, Expired	25.08	0
Weighted average grant date fair value, Cancelled	0	0.58
Weighted average grant date fair value, Ending	0.38	2.12
Weighted average grant date fair value, Options exercisable end of period	$ 0.38	$ 2.12

Options (Details 1)

Options (Details 1) - USD ($)	3 Months Ended		6 Months Ended
	May 31, 2022	May 31, 2021	May 31, 2022	May 31, 2021
Stock based compensation expense components	$ 0	$ 1,435	$ 0	$ 11,985
Research and Development Expense
Stock based compensation expense components	0	1,127	0	9,719
Selling, General and Administrative Expenses
Stock based compensation expense components	$ 0	$ 308	$ 0	$ 2,266

Options (Details Narrative)

Options (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	May 31, 2022	May 31, 2021	May 31, 2022	May 31, 2021	Nov. 30, 2021	Nov. 30, 2020	May 31, 2020
Unrecognized compensation cost	$ 0	$ 0	$ 0	$ 0
Stock options vested	276,394		276,394				276,394
Number of options outstanding	1,489,500		1,489,500
Share-based compensation arrangement by share-based payment award, options, grants in period	0	0	0	0
Options exercised	$ 0	$ 0	$ 0	$ 0
Stock option share-based compensation forfeiture rate	4%	4%	4%	4%
Common shares, outstanding	33,092,665		33,092,665		33,092,665	23,678,105
Employee Stock Option Plan [Member]
Share-based compensation arrangement by share-based payment award, options, grants in period			1,819,767
Common shares, outstanding	3,309,267		3,309,267
Lower [Member]
Options granted, term			5 years
Upper [Member]
Options granted, term			10 years

Deferred Share Units (Details N

Deferred Share Units (Details Narrative) - USD ($)	May 31, 2022	May 31, 2021
Deferred Share Units
Common shares for issuance under deffered share unit	11,000
Share-based compensation arrangement by share-based payment award, number of shares available for grant	11,000	11,000
Share-based compensation arrangement by share-based payment award, number of shares available for outstanding	$ 0	$ 0

Warrants (Details)

Warrants (Details) - $ / shares	6 Months Ended
	May 31, 2022	Nov. 30, 2021	May 31, 2021	Nov. 30, 2020
Shares issuable upon exercise	21,160,314
Number outstanding	21,160,314	21,160,314	21,437,792	21,923,624
Firm Warrants 2018 [Member]
Shares issuable upon exercise	20,000,000
Number outstanding	20,000,000
Exercise price	$ 0.75
Expiry	Oct. 16, 2023
October 2018 Placement Agent Warrants [Member]
Shares issuable upon exercise	1,160,314
Number outstanding	1,160,314
Exercise price	$ 0.9375
Expiry	Oct. 16, 2023

Warrants (Details1)

Warrants (Details1) - shares	May 31, 2022	Nov. 30, 2021	May 31, 2021
Warrant outstanding, beginning	21,160,314	21,437,792	21,923,624
Warrant outstanding, ending	21,160,314	21,160,314	21,437,792
2018 Firm Warrants
Warrant outstanding, beginning	20,000,000	20,000,000	20,000,000
Warrant outstanding, ending	20,000,000	20,000,000	20,000,000
October 2018 Placement Agent Warrants
Warrant outstanding, beginning	1,160,314	1,160,314	1,160,314
Warrant outstanding, ending	1,160,314	1,160,314	1,160,314

Warrants (Details 2)

Warrants (Details 2)	6 Months Ended
	May 31, 2021 shares
Warrant outstanding, beginning	21,923,624
Issued	0
Expired	(485,832)
Exercised	0
Warrant outstanding, ending	21,437,792
2018 Firm Warrants
Warrant outstanding, beginning	20,000,000
Issued	0
Expired	0
Exercised	0
Warrant outstanding, ending	20,000,000
October 2018 Placement Agent Warrants
Warrant outstanding, beginning	1,160,314
Issued	0
Expired	0
Exercised	0
Warrant outstanding, ending	1,160,314
June 2016 Warrants
Warrant outstanding, beginning	277,478
Issued	0
Expired	0
Exercised	0
Warrant outstanding, ending	277,478
March 2018 Warrants
Warrant outstanding, beginning	441,666
Issued	0
Expired	(441,666)
Exercised	0
Warrant outstanding, ending	0
March 2018 Placement Agent Warrants
Warrant outstanding, beginning	44,166
Issued	0
Expired	(44,166)
Exercised	0
Warrant outstanding, ending	0

Warrants (Details Narrative)

Warrants (Details Narrative) - USD ($)	1 Months Ended				6 Months Ended
	Oct. 31, 2018	Mar. 31, 2018	Oct. 31, 2017	Jun. 30, 2016	May 31, 2022	Nov. 30, 2021	Nov. 30, 2020
Fair value of Pre funded warrants					$ 12,256,868
Warrants to purchase common stock shares					21,160,314
Common shares, issued					33,092,665	33,092,665	23,678,105
Warrants [Member]
Warrants to purchase common stock shares			18,181	322,981
Fair value of warrants		$ 279,086	$ 742,555	$ 1,175,190
Volatility rate	73.67%	70%	73.67%	64.10%	70%
Risk free interest rate		1.64%	1.64%	0.92%
Warrants exercisable price per share		$ 6	$ 12.50	$ 19.30
Dividend yield		0%	0%	0%
Expected life	3 years	3 years	3 years	5 years	3 years
Warrants to purchase additional common stock shares	441,666	44,166	181,818	161,490
Purchase price per share of warrants				$ 0.01
Warrant to acquire common shares				24,223
Warrants to purchase common stock price per shares		$ 7.50	$ 11	$ 16.10
Gross proceeds from common shares and warrants		$ 5,300,000	$ 4,000,000	$ 5,200,000
Aggregate of common shares issued		883,333	363,636
Exercise price per share		$ 6	$ 13.75
Estimated fair vaue		$ 1,115,480	$ 86,196
Risk free interest rate, minimum	2.44%	2.44%
Risk free interest rate, maximum	2.46%	2.46%
Firm Warrants 2018 [Member]
Warrants to purchase common stock shares	2,608,695
Fair value of warrants	$ 279,086				$ 461,697
Volatility rate	92%				92%
Risk free interest rate	3.02%				3.02%
Warrants exercisable price per share	$ 0.75
Dividend yield	0%				0%
Expected life	5 years				5 years
Underwritten public offering	827,970
Underwritten public offering per units	$ 0.75	$ 0.01			$ 0.75
Additional common stock shares issued	1,947,261
Pre-Funded Warrants	16,563,335
Firm Warrants	20,000,000
Placement Agent Warrants	1,160,314
Exercise of overallotment option per share	$ 0.74
Pre funded warrant issued	16,563,335
Pre-Funded warrant description per share	The 2018 Pre-Funded Units were offered to the public at $0.74 each and a 2018 Pre-Funded Warrant is exercisable at $0.01 per share. Each 2018 Firm Warrant is exercisable immediately and has a term of five years and each 2018 Pre-Funded Warrant is exercisable immediately and until all 2018 Pre-Funded Warrants are exercised
Placement agents to purchase common shares	1,160,314
Placement agents to purchase common shares per share	$ 0.9375
Common shares, issued	2,775,231
Placement Agent Warrants [Member]
Estimated fair vaue		$ 141,284

Income Taxes (Details Narrative

Income Taxes (Details Narrative)	3 Months Ended	6 Months Ended
	May 31, 2022 USD ($)	May 31, 2022 USD ($)
Unclaimed investment tax credits	$ 15,951,739	$ 15,951,739
Unclaimed investment tax credits expiring between 2025 and 2040	2,933,013	2,933,013
Canada
Non-capital loss carryforward	$ 62,427,238	$ 62,427,238

Contingencies (Details Narrativ

Contingencies (Details Narrative)	Oct. 12, 2021 CAD ($)	Nov. 07, 2019 USD ($)
Contingencies (Note 12)
Payment for settlement	$ 40,000	$ 1,600,000
Settlement expense	266,000
Contribution to settlement fund		$ 400,000
Payment for settlement from insurance coverage	$ 226,000

Financial Instruments (Details)

Financial Instruments (Details) - USD ($)	May 31, 2022	Nov. 30, 2021	Aug. 26, 2019
Financial Liabilities
Convertible debentures, carrying amount	$ 1,800,000	$ 1,751,483	$ 8,769
Convertible debentures, fair value	1,766,498	1,783,882
Promissory notes payable, carrying amount	167,693	165,878
Promissory notes payable, fair value	$ 167,693	$ 165,878

Financial Instruments (Details

Financial Instruments (Details 1)	6 Months Ended
	May 31, 2022 USD ($)
Undiscounted future cash flows	$ 11,722,363
Accounts Payable
Undiscounted future cash flows	4,285,339
Accrued Liabilities
Undiscounted future cash flows	2,712,045
Employee Costs Payable
Undiscounted future cash flows	2,671,154
Operating lease liability
Undiscounted future cash flows	86,132
Convertible Debentures
Undiscounted future cash flows	1,800,000
Promissory Notes Payable
Undiscounted future cash flows	167,693
Less Than 3 Months
Undiscounted future cash flows	11,679,297
Less Than 3 Months | Accounts Payable
Undiscounted future cash flows	4,285,339
Less Than 3 Months | Accrued Liabilities
Undiscounted future cash flows	2,712,045
Less Than 3 Months | Employee Costs Payable
Undiscounted future cash flows	2,671,154
Less Than 3 Months | Operating lease liability
Undiscounted future cash flows	43,066
Less Than 3 Months | Convertible Debentures
Undiscounted future cash flows	1,800,000
Less Than 3 Months | Promissory Notes Payable
Undiscounted future cash flows	167,693
Three To Six Months
Undiscounted future cash flows	43,066
Three To Six Months | Accounts Payable
Undiscounted future cash flows	0
Three To Six Months | Accrued Liabilities
Undiscounted future cash flows	0
Three To Six Months | Employee Costs Payable
Undiscounted future cash flows	0
Three To Six Months | Operating lease liability
Undiscounted future cash flows	43,066
Three To Six Months | Convertible Debentures
Undiscounted future cash flows	0
Three To Six Months | Promissory Notes Payable
Undiscounted future cash flows	0
Six To Nine Months
Undiscounted future cash flows	0
Six To Nine Months | Accounts Payable
Undiscounted future cash flows	0
Six To Nine Months | Accrued Liabilities
Undiscounted future cash flows	0
Six To Nine Months | Employee Costs Payable
Undiscounted future cash flows	0
Six To Nine Months | Operating lease liability
Undiscounted future cash flows	0
Six To Nine Months | Convertible Debentures
Undiscounted future cash flows	0
Six To Nine Months | Promissory Notes Payable
Undiscounted future cash flows	0
Nine Months To One Year
Undiscounted future cash flows	0
Nine Months To One Year | Accounts Payable
Undiscounted future cash flows	0
Nine Months To One Year | Accrued Liabilities
Undiscounted future cash flows	0
Nine Months To One Year | Employee Costs Payable
Undiscounted future cash flows	0
Nine Months To One Year | Operating lease liability
Undiscounted future cash flows	0
Nine Months To One Year | Convertible Debentures
Undiscounted future cash flows	0
Nine Months To One Year | Promissory Notes Payable
Undiscounted future cash flows	0
Greater Than One Year
Undiscounted future cash flows	0
Greater Than One Year | Accounts Payable
Undiscounted future cash flows	0
Greater Than One Year | Accrued Liabilities
Undiscounted future cash flows	0
Greater Than One Year | Employee Costs Payable
Undiscounted future cash flows	0
Greater Than One Year | Operating lease liability
Undiscounted future cash flows	0
Greater Than One Year | Convertible Debentures
Undiscounted future cash flows	0
Greater Than One Year | Promissory Notes Payable
Undiscounted future cash flows	$ 0

Financial Instruments (Detail_2

Financial Instruments (Details Narrative)		1 Months Ended	3 Months Ended	12 Months Ended
	Oct. 12, 2021 CAD ($)	Nov. 30, 2020 USD ($)	May 31, 2022 USD ($)	Nov. 30, 2020 USD ($)
Other receivable within trade		$ 500,000		$ 500,000
Foreign exchange risk threshold balance			$ 1,000,000
Foreign exchange risk movement in currency percentage			10%
Foreign exchange rate loss and other comprehensive loss amount affected			$ 100,000
Initial payment of litigation received				2,000,000
Litigation expenses paid	$ 266,000
Purdue
Litigation expenses paid		$ 500,000		$ 2,000,000

Segmented Information (Details)

Segmented Information (Details) - USD ($)	3 Months Ended			6 Months Ended
	Feb. 28, 2022	May 31, 2021	Feb. 28, 2021	May 31, 2022	May 31, 2021	Nov. 30, 2021
Segmented Information
Revenue	$ 66,433	$ 93,427	$ 0	$ 16,978	$ 93,427
Total assets	1,889,571			1,881,583		$ 2,096,425
Total property and equipment	$ 942,631			$ 891,153		$ 994,109